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SUMMARY 
This body of work addresses the clinical dilemma posed by preterm preeclampsia. Firstly, we tested a 
potential therapeutic (esomeprazole) for the treatment of early preterm preeclampsia in a double-blind 
randomised controlled trial. The primary outcome of interest was prolongation of gestation, with 
secondary outcomes including maternal and perinatal outcomes. Importantly, this study was underpinned 
by extensive pharmacokinetic and biomarker studies on both plasma samples and placental tissue. We 
found that a daily dose of 40mg of esomeprazole did not prolong pregnancy in early preterm preeclampsia 
and there were no differences in maternal or neonatal outcomes or markers of endothelial dysfunction. 
The esomeprazole concentrations that were observed in our participants were within the lower range of 
concentrations used in our preclinical in vitro studies. We therefore concluded that 40 mg may not have 
been sufficient to have efficacy in treating preterm preeclampsia, and future studies should consider the 
role of a higher dose or intravenous administration, which has a higher exposure over time and peak 
concentration. 
Secondly, we assessed the impact of coexisting fetal growth restriction on pregnancy latency, obstetric, 
maternal and perinatal outcomes among women undergoing expectant management of early preterm 
preeclampsia. We found that the latency-to-delivery interval was significantly shorter among pregnancies 
with coexisting fetal growth restriction. These pregnancies were less likely to reach 34 weeks gestation 
and more likely to be delivered for suspected fetal compromise. More women with coexisting fetal growth 
restriction underwent an emergency caesarean section without a trial of labour induction and of those 
considered eligible for induction of labour, the rate of emergency caesarean section was higher among 
those with fetal growth restriction. Postnatally, the presence of coexisting fetal growth restriction was 
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associated with a higher rate of postnatal death and necrotising enterocolitis. Interestingly, the rate of 
maternal complications did not differ between the groups. We concluded that coexisting fetal growth 
restriction, diagnosed at the same time as preeclampsia, is an important determinant of pregnancy 
outcome among women being managed expectantly for early preterm preeclampsia. 
Thirdly, we sought to determine the role of expectant management of preeclampsia and the hypertensive 
disorders of pregnancy after 34 weeks gestation by assimilating the available data in a Cochrane 
systematic meta-analysis. Based on the limited data available, maternal outcomes appear better with 
planned early delivery for hypertensive disorders after 34 weeks’ gestation, but it is unclear whether this 
is associated with increased risks for the baby, especially at earlier gestations. It was not possible to 
determine whether planned early delivery was beneficial for different hypertensive conditions, 
particularly preeclampsia. We concluded that further studies are needed, preferably with reliable 
characterisation of hypertensive disease sub-types, to determine the ideal timing of delivery to optimise 
maternal and perinatal outcomes for hypertensive disorders of pregnancy occurring after 34 weeks 
gestation. 
This research provides new information about a candidate therapeutic for the treatment of preeclampsia.  
Clinical aspects of the hypertensive disorders of pregnancy that could further improve management are 
also discussed. 
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OPSOMMING 
Die inhoud van die werkstuk handel oor voortydse pre-eklampsie as ‘n kliniese probleem. Eerstens is ‘n 
potensiële terapeutiese middel (esomeprazol) vir die behandeling van voortydse pre-eklampsie getoets 
in ‘n dubble blinde ewekansige kliniese proef. Die primêre uitkoms van belang was verlenging van 
swangerskapsduurte, met moederlike en perinatale uitkomste as sekondêre uikomste. Daar was 
omvattende farmakokinetiese en biomerker studies op beide plasma en plasentale monsters gedoen 
gedoen. Ons vind dat ‘n daaglikse dosering van 40 mg esomeprazol nie swangskapsduurte met voortydse 
pre-eklampsie verleng het nie. Daar was ook geen verskille in moederlike en neonatale uitkomste en 
merkers van endoteel wanfunksie nie. Die esomeprazol konsentrasies soos waargeneem in deelnemers 
aan die studie was in die laer konsentrasie reikwydte van wat in die pre-kliniese in-vitro studies gebruik 
is. Ons gevolgtrekking is dus dat 40 mg nie voldoende was om pre-eklampsie te behandel nie. Toekomstige 
studies moet hoër of intraveneuse doserings oorweeg, met hoër blootstelling oor tyd en hoër piek 
konsentrasies. 
 
Tweedens het ons die impak ondersoek van meegaande fetale groei inkorting op swangerskaps latensie, 
verloskundige, moederlike en perinatale uitkomste van vroue met voortydse pre-eklampsie wat 
afwagtend hanteer is. Ons het gevind dat die latensie-tot-verlossing tydsverloop betekenisvol korter was 
in swangerskappe met meegaande fetale groei inkorting. Die swangerskappe het minder dikwels 34 weke 
swangerskapsduurte bereik en verlossing was meer algemeen vir vermoedelike fetal nood. Meer vroue 
met fetale groei inkorting het nood keisernsitte ondergaan sonder ‘n proef van induksie van kraam. Die 
met fetale groei inkorting wat kwalifiseer vir induksie van kraam het ook ‘n hoër noodkeisersnit insidensie 
gehad. Nageboorte was fetale groei inkorting geassosieër met ‘n hoër nageboorte sterftekoers en 
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nekrotiserende enterokolitis. Moederlike komplikasies tussen die groepe het interessant genoeg nie 
verskil nie. Ons gevolgtrekking is dat meegaande fetale groei inkorting wat saam met die pre-eklampsie 
gediagnoeer word, ‘n belangrike bepaler van swangerskapsuitkoms is, indien vroue afwagtend hanteer 
word met voortydse pre-eklampsie. 
 
Derdens het ons die waarde van afwagtende hantering van pre-eklampsie en hipertensiewe toestande 
van swangerskap na 34 weke swangerskapsduurte ondersoek deur beskikbare data te versamel in ‘n 
Cochrane oorsig. Die beperkte inligting dui daarop dat met hipertensiewe toestande na 34 weke 
swangerskapsduurte beplande vroeë verlossing moederlike uitkomste verbeter. Daar is onsekerheid of 
die hantering geassosieër is met verhoogde risikos vir die baba veral met vroeër swangerskapsduurte. Dit 
is ook nie moontlik om ‘n betroubare aanbeveling te maak oor beplande vroeë verlossing met verskillende 
hipertensiewe toestande, veral pre-eklampsie nie. Ons het tot die gevolgtrekking gekom dat verdere 
studies nodig is, met by voorkeur, betroubare beskrywing van die hipertensiewe siekte sub-tipe. Die ideale 
tydstip van verlossing kan dan bepaal word vir optimale moederlike en perinatale uitkomste van 
hipertensiewe toestande wat na 34 weke swangerskapsduurte ontwikkel. Die studies moet moederlike 
uitkomste soos mortaliteit, erge morbiditeit soos eklampsie, ‘n serebrovaskulêre ongeluk, pulmonale 
edeem, erge renale inkorting, lewer hematoom of ruptuur, lewerversaking, HELLP sindroom, diffuse 
intravaskulêre stolling, trombo-emboliese siekte en abruptio plasentae insluit. Perinatale uitkomste wat 
ingesluit behoort te word is fetale en neonatale sterftes, graad III of IV intravertrikulêre bloeding of 
intraserebrale bloeding, nekrotiserende enterokolitis, respiratoriese nood sindroom of graad III of IV 
hialiene membraan siekte, klein-vir-datum en neonatale konvulsies. Uitkomste wat ook ingesluit behoort 
te word is keisersnit insidensie en duurte van hospitaal verblyf van beide moeder en baba. 
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Die navorsing verskaf nuwe inligting oor ‘n kandidaat middel vir die behandeling van pre-eklampsie. 
Kliniese aspekte van hipertensiewe toestande van swangerkap wat hantering verder sal verbeter word 
ook bespreek. 
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CHAPTER 1. Introduction 
1.1 Background literature 
1.1.1 Burden of disease 
The hypertensive disorders of pregnancy are among the most common medical complications in 
pregnancy.1 Preeclampsia, the most serious of these complications, remains a leading contributor to 
maternal and perinatal mortality and morbidity worldwide. Preeclampsia is estimated to be responsible 
for 70,000 maternal deaths and over 500,000 perinatal losses every year. Further, it is estimated that for 
every preeclampsia related death there are between 50-100 women who experience significant 
morbidity.2 This burden is largely shouldered in low and middle income countries.3 In South Africa, high 
maternal and child mortality rates are recognised as a leading contributor to the ‘quadruple burden of 
disease’, along with the Human Immunodeficiency Virus epidemic, high levels of violence and increasing 
rates of non-communicable disease.  The hypertensive disorders of pregnancy remain a major contributor 
to maternal mortality in South Africa. They are responsible for 14% of maternal deaths and this proportion 
has not decreased over the past 20 years.4  
 
1.1.2 Definitions and classification systems 
There are many classification systems for the hypertensive disorders of pregnancy.5–9 Most agree that  
hypertension in pregnancy is defined as  systolic blood pressure greater than or equal to 140 mmHg and/or 
a diastolic blood pressure greater than or equal to 90 mmHg on the average of at least two measurements. 
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Severe hypertension is defined as systolic blood pressure greater than or equal to 160 mmHg or a diastolic 
blood pressure greater than or equal to 110 mmHg on at least two measurements. 
The four main hypertensive disorders of pregnancy include chronic hypertension, gestational 
hypertension, preeclampsia and superimposed preeclampsia on chronic hypertension.   
Chronic hypertension is defined as hypertension that is present before 20 weeks gestation or predates 
the pregnancy. Chronic hypertension usually persists postpartum and can be classified as primary or 
secondary to an underlying medical disorder.  
Gestational Hypertension is defined as hypertension that develops after 20 weeks of gestation without 
associated proteinuria or end organ involvement. It may progress during pregnancy to preeclampsia. The 
hypertension should resolve by 12 weeks postpartum and if not, the diagnosis of chronic hypertension is 
then made. 
Preeclampsia is defined as the new onset of hypertension with significant proteinuria or end-organ 
dysfunction, with or without proteinuria, after 20 weeks of gestation in a previously normotensive 
woman. End organ dysfunction includes renal insuffiency (defined as a serum creatinine concentration of 
more than 1.1mg/dL or ≥97.2μmol/L or doubling of the creatinine concentration in the absence of other 
renal disease), thrombocytopaenia (defined as platelet count < 100 000/microliter), impaired liver 
function (defined as transaminases at twice the normal concentrations), pulmonary oedema or cerebral 
or visual symptoms.9 The American College of Obstetricians (ACOG) does not include fetal growth 
restriction as evidence of end organ dysfunction but the International Society for the Study of 
Hypertension in Pregnancy (ISSHP) does. ISSHP also defines thrombocytopaenia as a platelet count less 
than 150 000/microliter.6,9 Preeclampsia with severe features includes women with preeclampsia who 
have severe hypertension, new-onset cerebral or visual symptoms including photopsia, scotomata, severe 
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headache and an altered mental state, pulmonary oedema, severe epigastric or right upper quadrant pain 
and a platelet count of less than 100 000/microliter.9  
Chronic hypertension with superimposed preeclampsia is defined by the new onset of significant 
proteinuria or end-organ dysfunction after 20 weeks gestation in a woman with underlying chronic 
hypertension. If a woman has chronic proteinuric hypertension before 20 weeks, superimposed 
preeclampsia is only diagnosed if there is significant loss of blood pressure control with an increase in 
proteinuria or end-organ dysfunction. 
In some settings, particularly in middle- and low-income countries, a woman may only seek antenatal care 
after 20 weeks gestation. If they have hypertension or hypertension with proteinuria they are said to have 
unclassified hypertension or unclassified proteinuric hypertension.10 The diagnosis is then reviewed 12 
weeks postpartum and they are reclassified into one of the above groups. 
In 2018 the International Society for the Study of Hypertensive Disorders in Pregnancy updated the 
guidelines and have discouraged the use of the terms severe preeclampsia or preeclampsia with severe 
features due to concerns that milder preeclampsia may be undertreated.11 
 
Preeclampsia can also be classified according to the gestation that it arises. Preterm preeclampsia occurs 
before 37 weeks gestation and is further divided into early preterm preeclampsia (before 34 weeks 
gestation) and late preterm preeclampsia (between 34 weeks and 37 weeks gestation).12 Term 
preeclampsia occurs after 37 weeks gestation. Other terminology commonly used to describe 
preeclampsia is early-onset versus late-onset disease, with early-onset disease defined as occurring 
before 34 weeks and late-onset disease after 34 weeks gestation. 
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1.1.3 Epidemiology 
Hypertensive disorders of pregnancy complicate 5-10% of pregnancies worldwide. It is difficult to 
determine the true incidence, particularly in low to middle income countries, as most estimates are 
hospital based and do not include births that occur in the home or outside the hospital.5 Of the 
hypertensive disorders of pregnancy, chronic hypertension comprises approximately 1%, gestational 
hypertension 3% and preeclampsia 2 to 4%.3 Early preterm preeclampsia is less common and makes up 
less than a third of all cases of preeclampsia.13 Most women with late-onset preeclampsia present after 
the 37th week of gestation.14 
 
The incidence of hypertensive diseases in pregnancy appears to be increasing, most likely due to the 
increase in high population attributable risk factors, such as obesity and increasing maternal age.15 Despite 
this, the incidence of eclampsia and other severe complications has decreased in high income countries, 
likely due to earlier detection and recourse to delivery.16,17 
 
Most deaths associated with the hypertensive disorders of pregnancy are due to preeclampsia. Among 
preeclamptic deaths, risk factors for maternal mortality include increasing maternal age, the need for 
preterm delivery and nulliparity. Black women and women who received no antenatal care are at higher 
risk of severe morbidity and mortality.18 The vast majority of preeclampsia related deaths occur in low 
income countries where there is limited access to health care facilities.19–21 Deaths in preeclampsia are 
most commonly due to cerebrovascular events (38.7%)  and in particular intracerebral haemorrhage.22 
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Other complications resulting in mortality include cardiac failure resulting in pulmonary oedema, renal 
failure, liver rupture or haemorrhage and haemolysis, elevated liver enzymes and low platelet (HELLP) 
syndrome.  
 
For every maternal death, it is estimated that 20 to 30 women suffer severe morbidity and 50 to 100 suffer 
significant morbidity.2,23 As with mortality, the morbidity associated with preeclampsia is largely 
shouldered in low- and middle-income countries.23 Maternal morbidities associated with the hypertensive 
diseases of pregnancy include neurological complications like eclampsia, stroke, retinal detachment and 
blindness, acute renal failure, pulmonary oedema, a hepatic haematoma with a possible rupture, HELLP 
syndrome and placental abruption. Adverse perinatal outcomes associated with the hypertensive 
disorders of pregnancy include stillbirth, neonatal death and fetal growth restriction.24  Perinatal 
outcomes associated with preeclampsia are significantly influenced by gestational age at delivery, 
particularly in low and middle income countries where access to advanced neonatal care is limited. While 
chronic hypertension and preeclampsia have been associated with an increased risk of preterm birth, it is 
preeclampsia that is the most significant contributor.25,26 
 
1.1.4 Pathogenesis 
The pathogenesis of preeclampsia is not completely understood, is multifactorial and involves maternal, 
fetal and placental contributors.  Placental tissue is nevertheless a prerequisite for developing the disease 
as evidenced by its association with gestational trophoblastic disease and cases of postpartum 
preeclampsia with retained products.27–29  
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Placental hypoperfusion resulting in hypoxia and ischaemia are key factors in the development of all 
preeclampsia. In early preterm preeclampsia defective trophoblast infiltration results in abnormal 
remodelling of spiral arteries with defective placentation and hypoperfusion. In late-onset preeclampsia 
an increasing placental mass without an increasing placental blood supply can result in hypoxia and 
ischaemia.30–34 The unifying downstream event is the elevated release of antiangiogenic factors, including 
soluble fms-like tyrosine kinase 1 (sFlt-1) and possibly soluble endoglin (sEng), from the ischaemic 
hypoperfused placenta. These circulating anti-angiogenic molecules are thought to cause widespread 
endothelial injury, 35–40 resulting in hypertension and end organ damage. 
 
1.1.5 Management of preeclampsia 
Early preterm preeclampsia 
There is currently no medical treatment available for preeclampsia aside from delivery. Preeclampsia is a 
progressive disorder and delivery is always in the best interests of the mother. At preterm gestation, this 
poses a particular dilemma, as clinicians are often forced to deliver early to prevent disease progression 
and major morbidity in the mother, but in doing so, expose the infant to the serious complications of 
prematurity. In particular, fetuses delivered severely preterm (at less than 32 weeks’ gestation) are at 
significant risk of death, or survival with severe disability including neurodevelopmental delay.41 It is for 
these reasons that expectant management of preeclampsia is undertaken at preterm gestation in carefully 
selected cases.  
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The aim of expectant management is to prolong gestation to benefit the fetus without risking maternal 
compromise. It is reasonable to offer expectant management from 24 weeks gestation depending on the 
accepted threshold for viability at the institution.42–44 In our setting, expectant management of early 
preterm preeclampsia is offered from 26 weeks.45 Two large observational studies have also supported 
the role of expectant management of early preterm preeclampsia, both reporting maternal safety.46,47 
Expectant management is usually undertaken in a tertiary unit with a dedicated team and access to a 
theater for emergency deliveries. Before expectant management is undertaken the mother is stabalized 
over a period of 24 to 48 hours and if major complications like eclampsia, pulmonary oedema, HELLP 
syndrome, clinical or moderate to severe ascites on ultrasound, renal impairment and fetal compromise 
are found, the pregnancy is delivered. Expectant management involves inpatient management with 4-
hourly blood pressure checks, a clinical examination twice a day, fetal monitoring, and routine blood work 
twice a week. All women are delivered at 34 weeks, or earlier if there is maternal or fetal compromise.45  
 
Three randomised trials have evaluated the role of expectant management versus expedited delivery. The 
first trial, by Odendaal et al. at Tygerberg Hospital, South Africa included 58 women with a gestational age 
between 28 and 34 weeks. There was a seven day gain in gestation with a decrease in the number of 
infants needing ventilation in the group managed expectantly.42 The second trial, by Sibai et al in North 
America, included 94 women with a gestational age between 28 and 32 weeks. In that trial, gestation 
increased by 15 days in the expectantly managed group, with a resultant decrease in neonatal intensive 
care admissions, respiratory distress syndrome and neonatal complications. Reassuringly, both these trials 
showed no increase in maternal complications. The third trial, the MEXPRE Study, from 8 sites in Latin 
America included 267 women who had severe preeclampsia with end organ symptoms like headache, 
visual disturbances, epigastric pain or more than 5 grams pf proteinuria. There was a significant 
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prolongation of pregnancy of 10 days versus 2 days in the expectantly managed group but no significant 
neonatal benefit. There was no difference in maternal morbidity although more placental abruptions were 
reported in the group managed expectantly. 48  
 
Expectant management aims to safely prolong gestation for the fetus and improve neonatal outcome, 
while not placing the mother at risk for severe complications.45 Currently there are no predictors for which 
pregnancies are more likely to have a longer latency while being managed expectantly.49 Two studies have 
assessed antenatally diagnosed fetal growth restriction as a possible predictor for adverse outcomes and 
have shown a shorter prolongation of pregnancy in women with preeclampsia and coexisting fetal growth 
restriction in women being managed expectantly for preterm preeclampsia.50,51 These studies have been 
limited by their retrospective design, and have not determined whether the presence of coexisting fetal 
growth restriction is associated with worse perinatal and maternal outcomes. 
 
Late preterm preeclampsia 
For pregnancies complicated by preeclampsia and other hypertensive disorders of pregnancy in the late 
preterm period (34 weeks- 37 weeks), the perinatal benefits of prolonging gestation are more modest, 
and the risk-benefit equation is weighted toward maternal safety.52,53 This creates uncertainty about the 
optimal gestation for delivery versus expectant management. Traditionally the management of 
preeclampsia after 34 weeks gestation has been a planned delivery, but there is currently a tendency to 
offer expectant management in the absence of maternal or fetal complications.  Planned early delivery 
may prevent maternal complications and prevent poor fetal outcomes like stillbirth, yet expectant 
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management may decrease the risks of prematurity for the neonate. These complications include 
respiratory distress syndrome, the need for ventilation and neonatal intensive care admission. 
 
The uncertainty on timing of delivery is best addressed by synthesising all available trial data that have 
examined perinatal and maternal outcomes in late preterm preeclampsia. This informs clinical 
management, as well as the design of any future interventional trials of potential therapeutic 
interventions for late preterm preeclampsia.  
1.1.6 Therapeutic interventions for preeclampsia 
The benefits of expectant management in preeclampsia would be maximized if there was a therapeutic 
agent available that could slow or arrest disease progression, allowing the fetus to safely gain gestation 
while minimizing maternal risk. Efforts to find a potential therapeutic for preeclampsia continue. 
Preeclampsia is characterized by maternal systemic inflammation and coagulation activation. 
Recombinant human activated protein C has been assessed in an open-label, single arm safety and efficacy 
trial.54 Reducing the quantity of the angiogenic factors sFlt-1 and sEng is currently the most promising 
approach for preeclampsia. Reducing circulating sFlt-1 and sEng has been addressed in two main ways; 
systemic removal by plasma apheresis or using agents that reduce placental production and release of 
sFlt-1 and sEng.  
 
Two small pilot studies have assessed serial apheresis treatments to target the removal of sFlt-1 from 
women with preterm preeclampsia.  The first trial showed a reduction in sFlt-1 accompanied by 
stabilization of blood pressure and a reduction in proteinuria.55 The second trial showed a stabilization in 
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sFlt-1 levels at baseline level.56 Both trials showed prolongation in pregnancy and no adverse maternal 
outcomes. A third trial, the Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women with 
Preeclampsia Via Apheresis (SAVE), is currently recruiting 23 women at 5 sites in the United Kingdom 
(NCT02923206). 
 
Recent preclinical laboratory studies have shown that proton pump inhibitors (PPI), particularly 
esomeprazole, have diverse biological actions making them a possible therapeutic for preeclampsia.57 
Esomeprazole decreases sFlt-1 and soluble endoglin production and release from primary trophoblast 
cells, as well as placental tissue explants and primary endothelial cells/tissues in both normal and 
preeclamptic pregnancies. Esomeprazole was also able to dilate whole human vessels from both normal 
pregnancies treated with a vasoconstrictor and vessels obtained from women with preeclampsia. These 
preclinical studies showed that esomeprazole had the additional advantage of decreasing endothelial 
dysfunction. Interestingly, in an in vitro model of tumor necrosis α–induced endothelial injury, the 
addition of esomeprazole reduced expression of endothelial vascular cell adhesion molecule-1, and 
reduced leucocyte adhesion to the endothelium. In vivo animal studies have also suggested that 
esomeprazole reduces blood pressure in a transgenic mouse model of preeclampsia where human sFlt-1 
is overexpressed in the placenta and released in excess into the maternal blood, mimicking human 
preeclampsia.58 Shafik et al have also shown that esomeprazole improved systolic blood pressure and 
prolonged the gestational period of preeclamptic rats.59 Subsequent to these laboratory findings, Saleh et 
al has reported that circulating sFlt-1 levels were lower among pregnant women at risk of developing 
preeclampsia who were coincidentally taking PPIs, compared with women who were not taking PPIs.60 
This key human data supports the laboratory findings that PPIs may be a candidate treatment for 
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preeclampsia, and is independent validation of the concept. Together, these findings suggest the potential 
for esomeprazole as a novel therapeutic agent for preterm preeclampsia. 
 
1.2 Purpose and scope of the research 
This body of work addresses the clinical dilemma posed by preterm preeclampsia in three ways. Firstly, 
our research team tested a potential therapeutic for the treatment of early preterm preeclampsia 
(esomeprazole) in a double-blind randomised controlled trial. The primary outcome of interest was 
prolongation of gestation, with secondary outcomes including maternal and perinatal outcomes. 
Importantly, this study was underpinned by extensive pharmacokinetic and biomarker studies on both 
plasma samples and placental tissue. Secondly, members of our research team assessed the impact of 
coexisting fetal growth restriction on pregnancy latency, obstetric, maternal and perinatal outcomes 
among women undergoing expectant management of early preterm preeclampsia. Thirdly, the  role of 
expectant management of preeclampsia and the hypertensive disorders of pregnancy after 34 weeks 
gestation was determined by assimilating available data in a Cochrane review 
 
1.3 Overall Objective 
This thesis addresses the management of preeclampsia remote from term, where we have tested a novel 
therapeutic for the treatment of preterm preeclampsia, identified fetal predictors of pregnancy outcome 
in preterm preeclampsia undergoing expectant management and evaluated the benefits of expectant 
management versus delivery in late preterm preeclampsia.  
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1.4 Hypotheses 
The following hypotheses were addressed in this thesis:  
1. That esomeprazole is an effective therapeutic for early preterm preeclampsia, allowing safe 
prolongation of gestation, without increasing maternal or fetal adverse outcomes; (Chapter 2) 
2. That the presence of coexisting fetal growth restriction is an important predictor of pregnancy 
latency and outcome among women undergoing expectant management for early preterm 
preeclampsia; (Chapter 3) 
3. That there is no significant difference between perinatal or maternal outcomes with expectant 
management of late preterm preeclampsia (Chapter 4) 
Each of the chapters begins with an overview of the work and is followed by published and unpublished 
manuscripts. The work consists of 3 peer reviewed published articles, published correspondence and one 
unpublished manuscript. 
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CHAPTER 2. Esomeprazole to treat women with preterm preeclampsia 
2.1 Overview 
There is no known treatment for preeclampsia apart from delivery. This is particularly devastating for 
pregnancies complicated by early preterm preeclampsia where clinicians are often forced to deliver a 
premature infant to reduce the risk of maternal morbidity and mortality. If a treatment were available 
that temporizes disease progression, it could be used to safely delay delivery and gain gestation, thereby 
decreasing the degree of prematurity and improving perinatal outcomes without putting the mother’s life 
at risk.  Such a treatment would have the greatest impact in low income countries like South Africa, where 
the disease burden is high, and recourse to preterm delivery is limited by access to advanced neonatal 
care. 
 
In pregnancies complicated by preeclampsia the placenta releases antiangiogenic factors which include 
soluble fms-like tyrosine kinase 1(sFlt-1) and soluble endoglin (sEng) into the maternal circulation which 
result in widespread endothelial damage. This results in the end organ disease seen in preeclampsia. 
 
Esomeprazole, a proton pump inhibitor, which is widely used in pregnancy to treat gastric reflux, has 
shown promise as a potential candidate therapeutic in preclinical studies. Esomeprazole has been shown 
to potently decrease sFlt-1 and sEng production and release from trophoblast and endothelial cells, dilate 
whole blood vessels, decrease endothelial dysfunction and decrease blood pressure in a transgenic mouse 
model of preeclampsia.57 
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These promising preclinical data encouraged us to perform a double-blind randomised controlled trial to 
assess a daily dose of 40 mg of esomeprazole for the treatment of early preterm preeclampsia. We 
published the trial protocol (section 2.2) and prospectively registered the trial with the Pan African Clinical 
Trials Registry. The trial was approved by the South African Medicines Control Council and Stellenbosch 
University Health Research Ethics Committee. 
 
We recruited 120 women at Tygerberg Hospital with pregnancies complicated with early preterm 
preeclampsia at a gestational age between 26 weeks and 32 weeks between January 2016 and April 2017. 
This is possibly the fastest recruitment rate for a treatment trial of preterm preeclampsia. The primary 
outcome was a prolongation of gestation by 5 days in the esomeprazole group. Secondary outcomes were 
maternal, neonatal and biochemical outcomes. We were the first to incorporate circulating markers of 
endothelial dysfunction associated with preeclampsia and pharmacokinetic studies in a preeclampsia 
treatment trial. 
 
There were no between-group differences in median time from randomization to delivery: median 11.4 
days (interquartile range, 3.6-19.7 days) in the esomeprazole group and 8.3 days (interquartile range, 3.8-
19.6 days) in the placebo group (3 days longer in the esomeprazole arm; 95% confidence interval, -2.9 to 
8.8; P=.31). There were no differences in maternal or neonatal outcomes or markers of endothelial 
dysfunction apart from a non-significant trend toward reduced placental abruption in the esomeprazole 
group. Esomeprazole and its metabolites were detected in maternal blood among those treated with 
esomeprazole at concentrations around the lower ranges tested in the in vitro laboratory studies. 
Reassuringly, only trace amounts were found in the umbilical cord blood. 
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We concluded that daily esomeprazole (40 mg) did not prolong gestation in pregnancies with preterm 
preeclampsia or decrease circulating soluble fms-like tyrosine kinase 1 concentrations. The esomeprazole 
concentrations that were observed in our participants were in the lower range of concentrations used in 
our preclinical in vitro studies. Thus, 40 mg of esomeprazole may not be sufficient to have efficacy in 
treating preterm preeclampsia, and future studies should consider the role of a higher dose or intravenous 
administration, which has a higher exposure over time and peak concentration.  
 
This chapter consists of the published trial protocol (Cluver et al 2015 BMJ Open)61 and the published trial 
manuscript (Cluver et al 2018, AJOG).62 Subsequent published correspondence, as well as the full trial 
protocol (including the patient information leaflet and consent form) can be found in the appendices. 
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2.2 Published protocol 
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2.3 Published manuscript 
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CHAPTER 3. The impact of coexisting fetal growth restriction on 
pregnancy outcomes in women undergoing expectant management for 
preterm preeclampsia 
3.1 Overview 
Early preterm preeclampsia is associated with serious complications for the mother and fetus. In well 
selected pregnancies, expectant management with close maternal and fetal surveillance, is established 
clinical practice. There are few clinical predictors that inform the likely prolongation of gestation in early 
preterm preeclampsia, but it might be expected that the presence of coexisting fetal growth restriction 
(FGR) would be an important contributor.  In two previous studies,50,51 coexisting fetal growth restriction 
has been associated with a shorter latency but were limited by being retrospective observational studies 
and provided limited data on maternal and perinatal outcome and no data on delivery outcomes. In this 
manuscript, a planned secondary analysis of the Preeclampsia Intervention with Esomeprazole (PIE) trial, 
we assessed whether antenatally diagnosed FGR influences the latency-to-delivery interval among 
women with preterm preeclampsia undergoing expectant management. Secondary aims were to 
determine if coexisting FGR influences the indication for delivery, mode of birth and the rate of maternal 
and perinatal complications. We defined FGR as an estimated fetal weight less than the 10th centile in this 
cohort. 
 
One hundred and eighteen women were included. Two participants from the PIE trial were excluded as 
one did not meet the trial requirements of preeclampsia and another declined inpatient management. 
Sixty-eight (57.6%) had fetal growth restriction, defined as an estimated fetal weight less than the 10th 
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centile on ultrasound, at the time of diagnosis of preeclampsia. The latency-to-delivery interval was 
significantly shorter among pregnancies with coexisting fetal growth restriction compared to those 
without (6.5 vs 16.3 days; median difference -9.8 days (95% CI -14.6 to -5.4), P=0.0004). These pregnancies 
were less likely to reach 34 weeks gestation (11.8% vs 30%, P=0.01) and more likely to be delivered for 
suspected fetal compromise (60.3% vs 36%, P=0.01). More women with coexisting fetal growth restriction 
underwent an emergency caesarean section without a trial of labour induction (66.2% vs 48%, P=0.05). 
Of those considered eligible for induction of labour, the rate of emergency caesarean section was higher 
among those with fetal growth restriction (89.5% vs 60%, P=0.01). Postnatally, the presence of coexisting 
fetal growth restriction was associated with a higher rate of postnatal death (17.6% vs 6%, P=0.04) and 
necrotising enterocolitis (10.3% vs 0%, P=0.005). The rate of maternal complications did not differ 
between the groups. 
 
We concluded that coexisting FGR, diagnosed at the same time as preeclampsia, is an important 
determinant of pregnancy outcome among women being managed expectantly for preterm preeclampsia. 
Coexisting FGR is associated with a shorter latency, more emergency deliveries, a lower chance of a 
successful induction, and increased rates of neonatal morbidity and mortality. 
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3.2 Manuscript 
 
  
Stellenbosch University  https://scholar.sun.ac.za
60 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
61 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
62 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
63 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
64 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
65 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
66 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
67 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
68 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
69 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
70 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
71 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
72 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
73 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
74 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
75 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
76 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
77 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
78 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
79 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
80 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
81 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
82 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
83 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
84 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
85 
 
 
CHAPTER 4. Planned early delivery versus expectant management for 
hypertensive disorders from 34 weeks gestation to term 
4.1 Overview 
The hypertensive disorders of pregnancy contribute significantly to maternal and perinatal morbidity and 
mortality. Definitive treatment involves delivery at any stage of the pregnancy. For pregnancies less than 
34 weeks, the risk-benefit ratio favours expectant management in well selected cases, with the aim to 
safely prolong gestation and improve both perinatal survival, and survival free of disability. For 
pregnancies between 34 weeks and term, the improvements in perinatal outcome are more modest which 
generates some uncertainty about the benefits and risks of a planned delivery versus expectant 
management. 
 
This thesis chapter describes a Cochrane systematic review, where we aimed to assess the benefits of a 
planned early delivery versus a policy of expectant management in women with hypertensive disorders 
of pregnancy between 34 weeks and term. We only included randomised trials. 
 
Five studies involving 1819 women were included. There was a lower risk of composite maternal morbidity 
and a lower risk of severe maternal morbidity for women who had a planned early delivery. There was 
insufficient information to draw conclusions on composite infant mortality and morbidity, but planned 
early delivery was associated with higher levels of respiratory distress syndrome and neonatal intensive 
care admissions. 
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Based on the limited data available, maternal outcomes appear better with planned early delivery for 
hypertensive disorders after 34 weeks’ gestation, but it is unclear whether this is associated with 
increased risks for the baby, especially at earlier gestations. It was not possible to determine from the 
studies to date whether planned early delivery was beneficial for particular hypertensive conditions, 
notably preeclampsia. 
 
Further studies are needed, preferably with reliable characterisation of hypertensive disease sub-type, to 
determine the ideal timing of delivery to optimise maternal and perinatal outcomes for hypertensive 
disorders of pregnancy occurring after 34 weeks gestation. These studies should include the maternal 
outcomes of mortality and severe morbidity like eclampsia, a cerebral vascular event, pulmonary oedema, 
severe renal impairment, a liver haematoma or rupture, liver failure, HELLP syndrome, disseminated 
intravascular coagulation, thromboembolic disease and placental abruption. Perinatal outcomes that 
should be included are fetal or neonatal death, grade III or IV intraventricular or intracerebral 
haemorrhage, NEC, RDS or grade III/IV, hyaline membrane disease, small-for-gestational age and neonatal 
seizures. The outcomes of the incidence of caesarean section, duration of hospital stay after delivery for 
mother and duration of hospital stay after delivery for baby should also be included. 
 
An abbreviated version of the review is available in section 2.2. The full review can be found in the 
appendices.  
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4.2 Cochrane review 
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CHAPTER 5: Conclusion and future directions 
5.1 Conclusion 
Preeclampsia remains one of the most common causes of maternal and perinatal morbidity and 
mortality.1,2 Making inroads into the global disease burden of preeclampsia is therefore an important 
imperative if we are to realize the goals set by the World Health Organisation to reduce the global 
maternal mortality ratio (MMR) to fewer than 70 maternal deaths per 100,000 live births by 2030.63 Much 
attention has been directed to screening for early preterm preeclampsia in early pregnancy, yet this is 
only a small part of the solution since screening modalities will not be able to identify all who are at risk 
of preeclampsia and preventative treatments, like aspirin, will not prevent all cases.64–66 Importantly, the 
global burden of preeclampsia occurs mostly in low resource settings, where screening and prevention is 
simply not feasible. This highlights the continuing need for an effective therapeutic for preterm 
preeclampsia that may delay or arrest disease progression. 
 
To have global impact, any treatment for preeclampsia ideally should be suited for low-and-middle 
income countries, ie. be cheap, off patent, widely accessible, well tolerated, have an established safety 
profile in pregnancy and not require prolonged refrigeration. A therapeutic target should ideally reduce 
placental production and release of antiangiogenic factors and improve maternal vascular function. 
Preclinical data suggested that proton pump inhibitors, specifically esomeprazole, met all these criteria. 
To translate these laboratory findings into the clinic, we performed a double-blind randomised controlled 
trial of 40 mg of daily esomeprazole versus placebo in which we not only obtained data on clinical 
outcomes, but we also derived important insights from integrating biomarker studies and 
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pharmacokinetics. Esomeprazole did not prolong gestation among women with early preterm 
preeclampsia in this trial, and there were no significant differences in maternal and perinatal outcomes 
by treatment group. Circulating levels of sFlt1 and other antiangiogenic markers were extremely high 
among the cohort and were not lowered by esomeprazole. The drug appeared safe and was well 
tolerated. In pharmacokinetic studies, we found that esomeprazole was present in the maternal 
circulation, but concentrations were relatively low compared with those required to elicit tissue/cell 
responses in our previous laboratory studies. This raises the possibility that higher doses, more frequent 
dosing or intravenous preparations may be necessary to see beneficial effects. Levels of esomeprazole in 
the umbilical cord blood were very low, or not detectable, which provides further reassurance that very 
little reaches the fetal compartment.  
 
Despite this negative finding, we have demonstrated our capacity to perform high quality therapeutic 
trials in settings where such interventions are needed most. Our trial was run at a single center, which 
allowed us to attain a high recruitment rate, closely monitor compliance, and collect uniform high-quality 
data including biospecimens.  We undertook parallel assessment of preeclampsia biomarkers and drug 
pharmacokinetics, which have helped identify potential reasons why the treatment may not have worked 
but have also been helpful to inform the design of future interventional trials. Importantly, by embedding 
this trial in an academic centre that serves a population with a high incidence of early preterm 
preeclampsia, we overcame the problem faced by previous trials of low recruitment. We propose this may 
be an optimal approach when designing clinical trials for early preterm preeclampsia. 
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Our future work proposes ongoing therapeutic trials of agents that may have efficacy to prevent, or treat, 
preeclampsia. With a focus on clinical translation, these drugs must first have a well-established safety 
profile in pregnancy, be cheap, accessible and well tolerated.  Our laboratory pipeline has enabled us to 
undertake the necessary in vitro and in vivo studies to identify which of these agents have the most 
promise; i.e.. reduce placental production and release of antiangiogenic factors, and reduce maternal 
endothelial dysfunction, both key pathological events in preeclampsia.  Through this program, we have 
identified new drug candidates. The research undertaken by the PhD has now set up a clinical trials 
infrastructure, which we plan to use to run a succession of clinical trials. The second interventional trial 
for treatment of early preterm preeclampsia with metformin is already well underway.  
 
We have shown that the presence of coexisting fetal growth restriction at the time of diagnosis is an 
important determinant of outcome in early preterm preeclampsia being managed expectantly. These 
pregnancies have a significantly shorter latency. Delivery is most likely to be triggered by a fetal indication 
and will almost universally end in caesarean section. The presence of coexisting FGR is associated with 
increased risks of neonatal mortality and serious morbidity. This high-quality prospective data usefully 
informs clinical counselling and decision making in women with early preterm preeclampsia. It is relevant 
to future therapeutic trials, where the fetal trigger for delivery may persist even if an effective intervention 
is identified that may slow maternal disease progression. 
 
Late preterm preeclampsia is associated with significant maternal morbidity. The available evidence 
favours delivery on maternal grounds, but limitations of existing data make it difficult to reliably ascertain 
the relative fetal benefit and risk. More research is needed with particular emphasis on stratification by 
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different disease sub-type and gestational age epochs. This would help with clinical decision making as 
well as the design of future interventional trials. If our future work identifies a safe and effective 
therapeutic for preeclampsia, these studies would determine whether expectant management and 
treatment could confer perinatal benefit without compromising maternal outcomes, even in late preterm 
preeclampsia.  
 
5.2 Future directions 
This research has created the momentum and infrastructure required to build research capacity and 
leadership in preeclampsia at Tygerberg Hospital, Stellenbosch University, South Africa. Our next steps 
include the testing of new therapeutics for preterm preeclampsia. We propose to test the most promising 
therapeutic candidates identified in the laboratory into clinical care, through testing them in appropriately 
powered randomised placebo-controlled trials (RCT). In the last 6 months we have commenced an 
interventional trial of metformin, and recruitment is already one third complete (n=56 out of a planned 
recruitment total of 150, as of October 2018).  The protocol has been submitted for publication. 
Importantly, our intervention has been appropriately informed by a preceding pharmacokinetics study of 
15 participants with preterm preeclampsia which shows a drug exposure profile that appears more 
promising than that seen with 40 mg of esomeprazole. 
 
Our vision is to continue running clinical trials of novel agents for the treatment of early preterm 
preeclampsia with embedded pharmacokinetics and mechanistic insights with clinical endpoints. 
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APPENDICES 
1. PIE trial protocol 
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The Pre-eclampsia Intervention with 
Esomeprazole (PIE) trial: 
a double blind randomised, placebo-controlled 
trial to treat early onset pre-eclampsia 
 
Phase II study 
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Full title of trial The Pre-eclampsia Intervention with 
Esomeprazole (PIE) trial: a double blind 
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treat early onset pre-eclampsia. 
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Version and date 22 August, 2014 
Version 2.4 
Ethics approval   
  
Protocol number M14/09/038 
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Institutional Review Board (IRB) Number: 
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Supervisors/ Co-investigators Professor Stephen Tong (external) 
Professor Susan Walker (external) 
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Abbreviations 
 
CTG Cardiotocograph 
FDA Food and Drug Administration 
GA Gestational age 
HO-1 Heme oxygenase-1 
ITT Intention to treat 
ISSHP International Society for the Study of Hyperensive disorders in Pregnancy 
KEAP-1 Kelch-like ECH-associated protein 1 
mg Milligrams 
Nrf-2 Nuclear factor (erythroid-derived 2)-like 2 
PIE Pre-eclampsia Intervention with Esomeprazole 
PPIs Proton pump inhibitors 
PRES Posterior reversible encephalopathy syndrome 
sEng Soluble Endoglin 
sFlt1 Soluble Fms Like Tyrosine Kinase -1 
STAMP STatins to AMeliorate early onset Pre-eclampsia 
TNF Tumour Necrosis Factor 
TR Treatment received 
VCAM-1 Vascular Cell Adhesion Molecule -1 
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1. Summary/ Synopsis 
 
Title 
The Pre-eclampsia Intervention with Esomeprazole (PIE) trial: a double blind randomised, 
placebo-controlled trial to treat early onset pre-eclampsia. 
 
Short Introduction and literature overview 
Pre-eclampsia is globally responsible for 60,000 maternal deaths per year, and far greater 
numbers of fetal losses. It is one of the leading causes of maternal mortality in South Africa and 
a major problem in developing countries. At present there is no treatment for pre-eclampsia 
apart from delivery which results in severe perinatal morbidity and mortality associated with 
prematurity. This is especially a problem in developing countries where there is a shortage of 
neonatal intensive care and high care beds. 
Esomeprazole is a proton pump inhibitor widely used for the treatment of gastric acid-related 
disorders, such as peptic ulcer disease and gastro-oesophageal reflux. Recently preclinical data 
has been generated showing that the proton pump inhibitor esomeprazole has potent biological 
effects making it a lead candidate to treat early onset pre-eclampsia.  
Esomeprazole: 
1) decreases the release of soluble endoglin (sEng) and soluble Fms-like Tyrosine Kinase 1 (sFlt-
1) from both primary placental tissue and primary endothelial cells in vitro. These are anti-
angiogenic factors released from the placenta that are thought to play a central role in the 
pathogenesis of pre-eclampsia. 
2) upregulates heme oxygenase-1, a potent ‘cytoprotective’ molecule in the placenta. 
3) decreases endothelial dysfunction in in vitro assays.  
Esomeprazole is inexpensive and is available in most developing countries. If proven to work it 
could have a major impact on maternal and perinatal health in developing countries. 
 
Research question 
Can a single daily dose of esomeprazole, compared with placebo, prolong gestation for a further 
5 days and improve biochemical markers in women with early onset pre-eclampsia managed with 
expectant management. 
 
Aims: 
Primary aim 
➢ To examine whether 40 mg of daily esomeprazole can safely further prolong 
 gestation for 5 days in women with early onset pre-eclampsia diagnosed 26+0 – 31+6 
weeks, compared to expectant management alone. 
 
Secondary aims 
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➢ To determine whether a single daily dose of 40 mg esomeprazole improves 1) maternal, 
2) fetal and 3) neonatal outcomes in early onset pre-eclampsia compared to placebo. 
➢ To examine whether a single daily dose of 40 mg esomeprazole can significantly decrease 
circulating levels of sFlt-1 and/ or sEng in women with early onset pre-eclampsia, 
compared to placebo. 
➢ To examine whether a single daily dose of 40 mg esomeprazole is safe and well tolerated 
in the mother, fetus and neonate compared with placebo. 
  
Methods (Overview) 
We will perform a double blind randomised controlled trial of 120 women with early onset pre-
eclampsia. Informed consent will be obtained. Pregnant women between the ages of 18 and 50 
years who present with early onset pre-eclampsia at a gestation of 26+0 to 31+6 weeks at 
Tygerberg Hospital who are considered stable enough to undergo expectant management will be 
randomised to either esomeprazole or placebo. They will receive either 40mg of daily 
esomeprazole or an identical placebo daily. The ongoing management and decision to deliver will 
be left to the discretion of the treating clinician who will be blinded to treatment group allocation. 
We will obtain clinical information, including maternal, fetal and neonatal outcomes, clinical 
investigation results of mother, fetus and neonate, and data on tolerability and safety. Blood 
samples and urine samples will be collected at enrolment and then twice weekly when routine 
blood are taken. At delivery we will collect a cord blood sample and placental tissue if consent 
has been given. 
 
Timeline 
4 years (2014 to 2017) 
 
Ethical considerations 
Pregnant women are a vulnerable population but early onset pre-eclampsia is a major cause of 
maternal, fetal and neonatal morbidity and mortality. Esomeprazole has been widely used in 
pregnancy and may be a treatment for this serious condition. For this reason we believe that it is 
important to conduct this trial. 
 
Anticipated overall outcome 
By the end of this phase II study, we will obtain evidence whether esomeprazole may be able to 
allow women diagnosed with early onset pre-eclampsia to safely gain gestation and whether it is 
a possible treatment option. 
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2.0 Background 
 
2.1 Introduction 
 
Pre-eclampsia is a major disease of pregnancy 
 
Pre-eclampsia is one of the most serious complications of pregnancy affecting 3-8 % of 
pregnancies worldwide 1,2. It is a multi-system disorder involving maternal vessels (causing 
hypertension and endothelial dysfunction), the kidneys, the liver, the lungs, the haematological 
system, the cardiovascular system and the fetoplacental unit3. In its most severe form, it affects 
the brain, causing seizures (eclampsia), cerebrovascular events and even death. 
It is a leading cause of maternal and fetal/neonatal morbidity4. Globally, pre-eclampsia is 
responsible for >60,000 maternal deaths annually5 and in South Africa hypertensive disorders 
of pregnancy are responsible for 14% of maternal deaths6. In the United States it is estimated 
that for every pre-eclampsia related death there are probably 50-100 other women who 
experience significant morbidity associated with pre-eclampsia7.  
 
There is no known treatment for pre-eclampsia apart from delivery 
 
Despite considerable research the only treatment available is termination/delivery of the 
pregnancy8. This poses a difficult clinical dilemma for early onset pre-eclampsia. Clinicians are 
often forced to deliver early on maternal indications to prevent major maternal morbidity (ie 
severe maternal organ injury), as there are no treatments to arrest disease progression, but in 
doing so, inflict severe prematurity on the fetus. In particular, fetuses delivered at less than 33 
weeks’ gestation are at significant risk of severe disability including cerebral palsy, stroke 
(intracerebral bleeding), retinopathy of prematurity, chronic lung disease and death9,10. 
Currently, there are trials investigating the possible use of pravastatin to treat pre-eclampsia 
(STAMP trial, UK based study), and to prevent it (Pravastatin for the Prevention of Pre-eclampsia, 
run by the MFM network, a US based study). There are no other significant trials of orally 
available small molecules to treat pre-eclampsia that we are aware of. 
 
Why is it important to find a treatment for pre-eclampsia? 
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If an affordable and safe treatment was available it could temporise the disease progression of 
pre-eclampsia thereby delaying delivery to gain gestation. This could save the lives of many 
infants and decrease the hospital burden caused by iatrogenic prematurity and is in keeping 
with the United Nations Development goals to reduce child mortality and improve maternal 
health. 
 
2.2 Pathogenesis of Pre-eclampsia  
 
Oxidative stress, anti-angiogenic factors and endothelial dysfunction: key steps in the 
pathogenesis of pre-eclampsia 
 
In normal pregnancy, the placenta implants and invades into the inner third of the myometrium. 
It remodels the maternal spiral arterioles, stripping them of the contractile smooth muscle and 
turning them into large non-contractile vessels. The maternal vascular system becomes a high 
capacitance (i.e. high volume) and low pressure system. This remodelling optimises the amount 
of maternal blood flow to the placental interface, maximising oxygen and nutrient exchange. 
 
In early pregnancy, the pre-eclamptic placenta fails to correctly implant in the myometrium. 
There is shallow placental implantation leading to inadequate remodelling of the spiral 
arterioles. The maternal arterioles become a low capacitance and high pressure system. As a 
consequence, there is less exchange of oxygen and nutrients and the placenta is rendered 
chronically hypoxic for the remainder of the pregnancy.  Chronic placental hypoxia may induce 
generalised vasoconstriction in the fetoplacental circulation with increased resistance to 
umbilical artery blood flow. In addition, the shallow implantation also results in chronic 
oxidative stress in the placenta11.  
 
There are other schools of thought that believe the primary insult during the first stage is 
predominantly oxidative stress and ischaemic/re-perfusion injury rather than hypoxia12. 
Whatever the mechanism of injury, most agree shallow placental implantation is an intrinsic 
key step to this first stage. 
 
In the second half of the pre-eclamptic pregnancy the persistent oxidative stress and hypoxia 
provokes the release of soluble Fms Like Tyrosine Kinase -1 (sFlt1)13 and soluble endoglin 
(sEng)14 into the maternal circulation. These are anti-angiogenic factors, released in vastly 
Stellenbosch University  https://scholar.sun.ac.za
133 
 
 
elevated amounts in pre-eclampsia13, which cause maternal endothelial dysfunction8 (injury to 
maternal vessels) and the end-organ injury seen with clinical disease3. 
 
Thus, key aspects in the pathophysiology of pre-eclampsia are 1) placental oxidative stress (and 
hypoxia) 2) placental release of the anti-angiogenic factors sFlt1 and soluble endoglin and 3) 
maternal endothelial dysfunction. A drug that can counter these pathological steps could be a 
strategy to treat pre-eclampsia. 
 
The greatest benefit for a potential therapeutic to treat pre-eclampsia would be one that could 
be administered to pregnancies diagnosed with early onset pre-eclampsia before 32-33 weeks. 
It is possible that such a therapeutic could significantly quench the disease process and stabilise 
the maternal condition. If so, it could allow the pregnancy to safely continue to a gestation where 
the risks to the fetus are much diminished (e.g. >34 weeks gestation). This could diminish the 
morbidity rates of many neonates, particularly in developing countries where babies of less than 
34 weeks gestation are very vulnerable. 
 
2.3 Biological role of proton pump inhibitors as possible 
therapy 
 
The proton pump inhibitor esomeprazole: an unexpected drug candidate for pre-eclampsia.   
 
The Translational Obstetrics Group at Melbourne University has generated strong preclinical 
evidence suggesting esomeprazole may have potent actions giving it significant potential as a 
treatment for pre-eclampsia (unpublished data). 
 
Esomeprazole counters three key steps in pre-eclampsia pathogenesis, by:  
 
1) Up-regulating heme oxygenase-1 (HO-1), a key cytoprotective enzyme with potent anti-
oxidant actions in cells. 
 
2) Strongly decreasing the release of antiangiogenic factors sFlt-1 and sEng. 
 
3) Quenching endothelial dysfunction. 
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2.3.1 Proton pump inhibitors up regulate a key placental protective 
enzyme: heme-oxygenase-1 
 
Seminal work during the 1970-80s revealed oxidative stress (present both in placenta and 
maternal vessels) is a key ingredient in the pathogenesis of pre-eclampsia15. Heme-oxygenase-1 
(HO-1) is a key cellular protection enzyme. It mobilises a number of anti-oxidant defenses and 
switches on cytoprotective genes16. It has been proposed that decreased HO-1 is important in 
the pathogenesis of pre-eclampsia and leads to increased oxidative stress seen in the disease17-
20. Many researchers have thus speculated that identifying a drug that up-regulates HO-1 could 
be an effective strategy to treat pre-eclampsia21. HO-1 has therefore emerged as a key 
molecule of interest in the field. 
The Translational Obstetrics Group has found that proton pump inhibitors (PPIs) potently 
upregulate HO-1 expression (ie a class effect common to all proton pump inhibitors) See Figure 
1.   
 
Figure 1: Proton Pump Inhibitors upregulate HO-1 
 
Specifically, esomeprazole was found to have extremely potent effects in inducing HO-1.  
Esomeprazole induced HO-1 by 11.5 fold in endothelial (primary HUVEC) cells and 3.9 fold in 
purified primary trophoblast cells. See Figure 2.  
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Figure 2: Esomeprazole upregulates heme oxygenase-1 in a dose dependent manner 
 
Thus, esomeprazole potently induces the anti-oxidant enzyme HO-1 in both primary human 
endothelial and trophoblast (placental) cells. This makes it an exciting candidate drug therapy for 
pre-eclampsia. 
 
Our current hypothesis is that proton pump inhibitors up-regulate HO-1 by increasing the levels 
of nuclear factor erythroid-derived 2-like 2 (NRF-2). NRF-2 is a transcription factor upstream of 
HO-1. Once activated, NRF-2 enters the nucleus and activates a host of genes that have anti-
oxidant actions, especially HO-1, that up-regulate genes in the oxidative phosphorylation 
pathway (beneficial to counteract hypoxia).  The Translational Obstetrics Group has shown that 
PPIs induce NRF-2 translocation into the nucleus (data not shown). 
 
NRF-2 is usually bound by Kelch-like ECH-associated protein 1 (KEAP-1) and targeted for 
degradation. KEAP-1 is a molecular sensor of oxidative stress and also senses other molecules 
including drugs. While not yet proven in the laboratory, our hypothesis is that KEAP-1 senses PPIs 
which induce a structural change in KEAP-1. In the new confirmation state, KEAP-1 is less able to 
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bind and degrade NRF-2. NRF-2, free from KEAP-1, is then able to enter the cells and up-regulate 
anti-oxidant genes, including HO-1.  
 
2.3.2 Proton pump inhibitors block the release of sFLt-1 and soluble 
endoglin (sEng) 
 
A major advance in the field of pre-eclampsia was made with the identification of sFlt-1 and 
sEng as the likely ‘toxins’ released from the placenta causing the severe maternal organ end-
injury seen in pre-eclampsia20. Their effect is probably mediated via anti-angiogenic 
mechanisms. 
 
The evidence implicating sFlt-1 and sEng as central to the pathogenesis of pre-eclampsia is 
compelling22. Serum sFlt-1 and sEng are increased in women with pre-eclampsia many weeks 
preceding clinical disease and there is a dose dependent relationship between serum levels and 
disease severity14. sFlt-1 administered in vivo to pregnant rats can induce hypertension and 
proteinuria23. Impressively, co-administration of both sFlt-1 and sEng in pregnant rats 
recapitulates the entire spectrum of end-organ injury seen in severe pre-eclampsia24. sFlt-1 and 
sEng are, by far and away, the most studied molecules in the field of pre-eclampsia. 
Blocking sFlt-1 and sEng release is therefore a potential therapeutic strategy to treat pre-
eclampsia. sFlt-1 and sEng are present in the serum of normal pregnancies, and increase with 
advancing gestation14. Thus, an effective therapeutic may only need to decrease levels and it 
may not be necessary to completely abolish production altogether. 
 
The acceptance of the strategy to reduce levels of these anti-angiogenic factors as a means to 
treat pre-eclampsia is highlighted by the design of the ‘Statins to Ameliorate early onset Pre-
eclampsia’ (STAMP) trial21. This UK based trial which has been approved by the University of 
Birmingham seeks to examine the potential of using pravastatin to treat early onset pre-
eclampsia, and is the only significant randomised trial of an oral agent to treat early onset pre-
eclampsia that we are aware of. The primary outcome of this trial is to show a significant 
reduction in serum sFlt-1. 
 
The Translational Obstetrics Group has generated preclinical data showing esomeprazole 
induces marked decreases in sFlt-1 and sEng in both primary endothelial and trophoblast cells 
(see figure 3). The reductions are extremely potent: the highest dose of esomeprazole of 100 
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uM decreased sFlt-1 in primary trophoblast by >50% (Fig 3B) and reduced sEng by >90% (Fig 
3D). 
 
Figure 3: Esomeprazole decreases sFlt1 and soluble endoglin release 
 
To confirm the choice of esomeprazole as the best candidate in the proton pump inhibitor 
group it was tested against 4 other proton pump inhibitors. The effect on sFlt-1 and soluble 
endoglin was measured (see figure 4). Esomeprazole again had the most potent dose 
dependent effect (data still to be published). 
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Figure 4: A comparison of five proton pump inhibitors shows esomeprazole is the most potent 
in reducing sFlt-1 and sEng. 
 
Pravastatin entered clinical trials on the strength of preclinical data generated from rodent 
animal models25-27. Surprisingly, there has been a lack of published data reporting whether it 
can reduce sFlt1 and sEng production from human blood vessels and placenta. The 
Translational Obstetrics Group examined pravastatin using the same assays done for 
esomeprazole (ie Figure 3). At the same doses used to test the proton pump inhibitors (5, 50, 
100 uM), pravastatin had no effect on either sFlt-1 or sEng production. Dose response 
experiments showed that when the pravastatin dose was increased to 2000 UM (20 times the 
top dose of esomeprazole) sFlt-1 only showed a 30% drop in level and there was actually a dose 
dependent increase of sEng. Therefore, in functional assays using primary human tissues, 
esomeprazole appears to considerably outperform pravastatin in potency and desired effect. 
 
Stellenbosch University  https://scholar.sun.ac.za
139 
 
 
Currently, we are not aware of any other candidate drugs in the literature that induce such 
potent reductions in these anti-angiogenic factors and that decreases both of these anti-
angiogenic factors as the proton pump inhibitor group does.  
 
2.3.3 Proton pump inhibitors decrease endothelial dysfunction of blood 
vessels 
 
A hallmark of pre-eclampsia is endothelial dysfunction, a form of maternal blood vessel injury20. 
It is the likely reason that raised blood pressure is one of the most predictable clinical responses 
in an illness that is notorious for its varied clinical presentations. 
 
When endothelial dysfunction occurs, the blood vessels express adhesion proteins on the cell 
surface, principally Vascular Cell Adhesion Molecule -1 (VCAM-1)28. VCAM-1 directly binds to 
leukocytes, causing leukocyte adhesion to the vascular endothelium. With dysfunction, 
endothelial cells also release endothelin-1, a potent vasoconstrictor, into the circulation. Levels 
of endothelin-1 are increased with pre-eclampsia29. VCAM-1 and endothelin-1 are widely 
accepted as markers of endothelial dysfunction28.  
 
The Translational Obstetrics Group has recently found that esomeprazole potently blocks up-
regulation of VCAM-1 and endothelin-1 induced by Tumour Necrosis Factor- (TNF-), an 
inflammatory molecule involved in endothelial dysfunction (see Figure 5). The effects were very 
potent: at the top dose of esomeprazole, VCAM-1 mRNA is undetectable and mRNA of 
endothelin 1 is reduced by >80% (data still to be published). 
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Figure 5: Esomeprazole quenches endothelial dysfunction 
 
Thus, esomeprazole may be able to powerfully quench endothelial dysfunction, a hallmark of 
pre-eclampsia. 
 
The preclinical evidence presented in this application has been derived from functional studies 
using primary human tissues, not immortalized cells. Thus, generated from primary human 
tissues, this data represents a high level of preclinical evidence. Secondly, all data presented were 
derived from the mean of at least three biological replicates (ie each experiment was repeated 
at least three times). The preclinical data is therefore robust. 
 
2.3.4 Animal Models for pre-eclampsia 
 
Unfortunately pre-eclampsia is a disease that is seen only in humans and there are no 
convincing animal models of pre-eclampsia. 
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There are a number of animal models that have been proposed but differences in placentation 
among mammals make the search for a model that satisfies the criteria of pre-eclampsia a 
challenge30. For instance, for cloven-hoofed mammals such as sheep, normal placental 
implantation is very shallow. This severely limits their utility to model the poor placental 
invasion of maternal spiral arteries given normal invasion is already shallow31. In non-primate 
humans like monkeys and baboons the full spectrum of pre-eclampsia has never been reported. 
Placental implantation of guinea pigs is generally deeper and therefore more similar to humans, 
but these animals also do not exhibit the signs and symptoms of pre-eclampsia30,32. There are 
some mouse models of pre-eclampsia where the anti-angiogenic factors are inserted into the 
mice by plasmids and the protein levels artificially over-expressed. While they can recapitulate 
increased anti-angiogenic factor production, hypertension and even maternal end-organ injury, 
they are a little less convincing as they do not model shallow placental implantation that is a 
key pathophysiological step in pre-eclampsia. 
 
Furthermore, we propose esopremazole acts by decreasing oxidative stress, decreasing release 
of anti-angiogenic factors and decreasing endothelial dysfunction. There is no animal model of 
preeclampsia that has all three elements of oxidative stress, elevated release of anti-angiogenic 
factors and endothelial dysfunction.  
 
In summary, studies on pre-eclampsia treatment are limited by the fact that there are no 
accurate animal models. This makes it extremely difficult to test new medications and doses as 
initial trials need to be performed on humans to assess applicable doses efficacy. 
 
 
2.4 Proton Pump inhibitors 
 
2.4.1 Safety data in pregnancy 
 
Proton pump inhibitors have been commonly used in pregnancy to treat gastroesophageal 
reflux disorders and more serious gastrointestinal complications like Helicobacter pylori-
infection, peptic and duodenal ulcers and Zollinger-Ellison syndrome35. 
 
2.4.1.1 Animal studies: 
 
Reproductive studies have been performed on rats and rabbits, with doses greater than 57 
times and 35 times respectively of the human dose of 40mg36. These doses have revealed no 
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evidence of impaired fertility or teratogenicity to the fetus. Changes in bone morphology were 
observed in offspring of rats dosed through most of pregnancy and lactation at doses equal or 
greater than 33.6 times an oral human dose of 40mg. (Nexium product information). These 
changes were reversible after birth. 
 
2.4.1.2 Human studies 
 
Esomeprazole has recently been reclassified as a Category C drug in pregnancy from a 
Pregnancy Category B drug by the Food and Drug Administration (FDA). Category B is for 
medications where studies in animals have not shown a risk to the fetus but where adequate 
data in humans are not available37. Category C is for drugs where animal reproduction studies 
have shown an adverse effect on the fetus and there are no adequate and well-controlled 
studies in human, but potential benefits may warrant use of the drug in pregnant women 
despite potential risks38. 
The reason for changing the classification of esomeprazole was based on the above animal 
studies where bone changes were noted. In human pregnancies doses equal to 33.6 times the 
oral human dose of 40mg are never used. There have been no reports of changes in bone 
morphology in newborns exposed to esomeprazole during pregnancy (Nexium product 
information). 
 
The Australian categorisation system and database for prescribing medicines in pregnancy 
classifies esomeprazole as a category B3 drug in pregnancy. A category B3 drug is one that has 
been taken by a limited number of pregnant women and women of childbearing age, without 
an increase in the frequency of malformation or other direct or indirect harmful effects on the 
human fetus having been observed and where animal studies have shown evidence of an 
increased occurrence of fetal damage, the significance of which is considered uncertain in 
humans. (http://www.tga.gov.au/hp/medicines-pregnancy.htm) 
 
One nested case control analysis which suggested a possible link with proton pump inhibitors 
and septal cardiac birth defects. The authors suggested that this result be confirmed with larger 
observational studies39. Larger observational studies have not proven this to be true. 
Large population based cohort studies and systematic reviews (including administration during 
the first trimester) did not find adverse effects in pregnancy. Specifically, these studies did not 
find an increased risk of congenital defects or any adverse neonatal outcomes. The most recent 
systematic literature review published in 2009 included 1530 pregnancies exposed to proton 
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pump inhibitors and had 133,410 non-exposed matched controls. There was no increase in 
major congenital abnormalities, no increased risk of spontaneous miscarriages or preterm 
delivery35. 
The largest study to date, published in 2010, spanned a 13 year period and involved 840,968 
pregnancies of which 5082 were exposed to proton pump inhibitors in the first trimester of 
pregnancy. This study concluded that exposure to proton pump inhibitors, even during the first 
trimester of pregnancy, was not associated with an increased risk of major birth defects40. In 
2012, a further large study involving 112 022 pregnancies of which 1 186 pregnancies had been 
exposed to proton pump inhibitors confirmed there was no associated increase risk for 
congenital anomalies with proton pump inhibitor use. Importantly this study also found no 
increase in fetal growth restriction or adverse neonatal outcomes (including premature delivery 
and low Apgar scores) in pregnancies exposed to proton pump inhibitors in the first, second or 
third trimesters of pregnancies41. 
 
Pravastatin has been assigned to pregnancy category X by the FDA and the Australian 
categorisation system and database for prescribing medicines in pregnancy. The Australian 
system classifies drugs that have a high risk of causing permanent damage to the fetus as 
category X. They feel that these drugs should not be used in pregnancy or when there is a 
possibility of pregnancy. The FDA classifies category X drugs in pregnancy as medications where 
studies in animals or humans have demonstrated fetal abnormalities and/or there is positive 
evidence of human fetal risk based on adverse reaction data from investigational or marketing 
experience, and the risks involved in use of the drug in pregnant women clearly outweigh 
potential benefits. Despite this, pravastatin has been approved for trials in women with early 
onset preeclampsia (STAMP trial) and for women at risk of developing preeclampsia. In both of 
these studies the risk to the mother of early onset preeclampsia was felt to warrant trials with a 
category X drug.  
 
We are proposing a similar trial design for the same medical condition with a drug where the 
classification systems state that use may be of benefit in certain clinical situations. 
Esomeprazole and other proton pump inhibitors have been used in thousands of human 
pregnancies no increase in fetal growth restriction or adverse neonatal outcomes (including 
premature delivery and low Apgar scores) in the first, second or third trimesters of pregnancies. 
We will only be using treatment for a relatively short period in the late second and early third 
trimesters. 
 
2.4.2 Esomeprazole drug information 
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Product information on esomeprazole can be found at the following link: www1.astrazeneca-
us.com/pi/Nexium.pdf 
 
2.4.2.1 Dosage 
 
Esomeprazole is available as delayed-release tablet sachet or capsule for oral administration in 
two strengths: 20mg and 40mg. The standard dosage for the treatment of gastroesophageal 
reflux disease is 20 to 40mg once daily. We will be giving our participants a single daily dose of 
40mg.  
 
There is currently no pharmacokinetic data available on pregnant women using esomeprazole as 
they are were excluded from the original phase 1 trials.  
 
We have decided to use the standard dose of 40mg daily (rather than 20mg) after reviewing the 
available pharmacokinetic data on esomeprazole42,43.  40mg provides a longer steady state and 
better suppression of symptoms. Pregnancy is associated with haemodilution and for this reason 
40mg may already result in lower levels than in non-pregnant women. As such, we would be 
concerned 20mg could be less efficacious given the haemodilution seen in pregnancy. 
 
Notably, 40mg is a dose that has been used in pregnancy in the late second and third trimester. 
This dose appears adequate in providing substantial symptomatic relief from reflux implying it 
results in adequate maternal circulation drug levels and an efficacious therapeutic response. 
Critically, large cohort studies (equivalent to post-marketing surveillance data done in large 
populations after the release of any drug) did not find this drug to be associated with adverse 
effects among pregnant women.  
 
We do not feel comfortable using higher dosages as there is no published data examining the 
safety of higher doses have in pregnancy. Furthermore, given there are no adequate animal 
models of pre-eclampsia, we cannot use in vivo animal models to guide us in deciding whether 
an alternative dose other than 40mg is more appropriate.  
If esomeprazole was proven to be a treatment option for pre-eclampsia, then we have the option 
then of instigating further larger multicentre trials to test different doses. Currently it is not 
pragmatically viable for us to do a multiarm study examining different doses given the numbers 
needed would be prohibitively large.   
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2.4.2.2 Contraindications 
 
Esomeprazole is contraindicated in patients who have a known hypersensitivity to proton pump 
inhibitors. For this reason a previous hypersensitivity reaction to proton pump inhibitors will be 
an exclusion criterion for the study. 
 
2.4.2.3 Warnings and precautions 
There may be a small risk of clostridium difficile associated diarrhoea in severely ill patients. Our 
participants will be closely monitored for any effects of the medication and if significant 
diarrhoea develops the trial nurse will urgently notify the attending clinician and will inform them 
of the potential risk of clostridium difficile associated diarrhoea.  
 
2.4.2.4 Adverse reactions 
The most common adverse reactions in adults are headache, diarrhoea, nausea, flatulence, 
abdominal pain, constipation and a dry mouth. Caution will be exercised as some of these 
symptoms overlap with those of pre-eclampsia. All participants will be given an information sheet 
about all the possible effects of esomeprazole. 
 
2.4.2.5 Drug interactions 
Antiretroviral drugs  
Decreased serum levels of the antiretroviral drugs atazanavir and nelfinavir have been reported 
with the use of omeprazole. This could lead to antiretroviral drug resistance and concomitant use 
is therefore not recommended. Increased serum levels have been reported with the concomitant 
use of omeprazole with saquinavir. A decrease in the dose of saquinavir may be indicated if used 
together. For these reasons, women using the above antiretroviral medication will be ineligible 
for our study.  
 
Drugs for which gastric pH can affect bioavailability 
Esomeprazole inhibits gastric acid secretion so the absorption of drugs such as digoxin may 
increase with concomitant use and the absorption of drugs such as ketoconazole and iron salts 
may be decreased.  
 
Women using digoxin and ketoconazole will be excluded from the study. Most pregnant women 
with anaemia at Tygerberg Hospital are treated with iron salts. We will therefore monitor 
haemoglobin levels to ensure anaemia is not developing due to a lack of iron absorption 
potentially caused by esomeprazole. 
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Effects on hepatic metabolism 
Esomeprazole is metabolised by the CYP 2C19 and CYP 3A4 pathways in the liver.  
It can potentially interfere with the CYP 2C19 pathway and may result in a decreased clearance 
of diazepam, estimated to be a 45% decrease. If a mother is using diazepam she will not be 
eligible for the study. 
 
Clopidogrel is an antiplatelet agent that is partially metabolised to its active agent by the CYP2C19 
pathway. Therefore the concomitant use of esomeprazole with clopidogrel should be avoided as 
esomeprazole decreases the activity. Clopidogrel is rarely used in pregnancy. However, if a 
mother is on this treatment she will not be eligible for the study. 
 
Drugs known to induce the CYP2C19 or CYP3A4 pathways like St John’s Wort or rifampicin can 
substantially decrease esomeprazole concentrations and should not be used in combination with 
esomeprazole. The use of these medications will be an exclusion criterion. 
 
Effects on renal impairment 
Data is limited in patients with impaired renal function, but patients will be delivered before 
significantly elevated levels of serum creatinine are reached.  
 
Other medications 
The use of the following medications will be an exclusion criterion for this study since 
esomeprazole may affect their bioavailability: 
• Warfarin 
• Voriconazole 
• Cilostazol 
• Tacrolimus 
• Erlotinib 
• Methotrexate 
These medications are not generally used in pregnancy. 
 
2.4.2.6 Mechanism of action 
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific 
inhibition of the H+/K+ ATPase in the gastric parietal cell.  
 
As discussed, esomeprazole appears to 1) up regulate HO-1 2) decrease production of sFlt-1 and 
sEng and 3) decrease markers of endothelial dysfunction in endothelial cells. We have yet to 
elucidate the exact molecular target that esomeprazole directly interacts with to elicit these 
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changes. However, they are likely to be independent to its effects that cause proton pump 
inhibition.  
 
As noted above, we postulate the up regulation of HO-1 may be mediated through a direct 
interaction of esomeprazole and KEAP-1. This releases NRF-2 which translocates to the nucleus 
and up regulates a raft of genes (including HO-1) involved in anti-oxidant defences.  
 
2.4.2.7 Pharmacokinetics 
Esomeprazole is 97% bound to plasma proteins and is metabolised by the liver. The metabolites 
lack antisecretory activity. The plasma elimination half-life is about one to one and a half hours. 
Less than 1% of the parent drug is excreted in the urine with 80% being excreted as inactive 
metabolites in the urine and the rest excreted as inactive metabolites in the faeces.  
 
2.5 Summary  
Currently, the only option for the treatment of pre-eclampsia is delivery.  At extremely premature 
gestations this subjects the neonate to the risk of significant morbidity and mortality.  
 
Preclinical data has uncovered potent biological actions suggesting esomeprazole may be a lead 
candidate therapeutic to treat pre-eclampsia. Treatment with a proton pump inhibitor in the late 
second trimester or early third trimester, which is well after organogenesis has occurred, for a 
relatively short period, is likely to have a negligible risk of causing fetal anomalies and adverse 
perinatal outcomes.  
 
We have commenced a unique collaboration between Stellenbosch and Melbourne University 
that will allow us to test this hypothesis in Tygerberg Academic Hospital, South Africa. This 
population has a high prevalence of early onset pre-eclampsia. A trial of similar size in the 
developed world would require much larger numbers of participating sites. 
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3.0 Aims and Objectives 
 
3.1 Specific Aims and Outcomes:  
 
Primary aim: 
1) To examine whether a single daily dose of 40 mg of esomeprazole can safely prolong 
gestation for an additional 5 days in women with early onset pre-eclampsia diagnosed 
26+0 – 31+6 weeks who are being managed expectantly compared to expectant 
management alone. 
 
Primary outcome: 
1) Prolongation of gestation measured from the time of enrolment to the time of delivery, 
in hours and days. 
 
Secondary aims: 
2) To determine whether esomeprazole can improve 1) maternal 2) fetal and 3) neonatal 
outcomes in early onset pre-eclampsia being managed expectantly compared to 
expectant management alone. 
3) To examine whether 40 mg of daily esomeprazole can significantly decrease levels of 
circulating sFlt-1 and/or sEng in women with early onset pre-eclampsia who are being 
managed expectantly compared to expectant management alone. 
4) To examine whether 40 mg of daily esomeprazole is safe and well tolerated in the mother 
and infant, compared with placebo. 
 
3.2 Hypothesis 
 
Primary Hypothesis: 
1) 40 mg of daily oral esomeprazole can safely prolong gestation for at least a further 5 days 
in women with early onset pre-eclampsia diagnosed between 26+0 – 31+6 weeks, 
compared to expectant management alone. 
Other hypotheses: 
2) 40 mg of daily oral esomeprazole can improve maternal, fetal and neonatal outcomes, 
in women diagnosed with early onset preeclampsia, compared to expectant 
management alone. 
3) 40 mg of daily oral esomeprazole can significantly decrease the circulating levels of sFlt1 
and sEng in early onset preeclampsia being managed expectantly compared to expectant 
management alone. 
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4) 40 mg of daily oral esomeprazole is safe and well tolerated in the mother, fetus and infant. 
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4.0 Study Design 
 
4.1 Type of study 
 
Hospital based phase II placebo-controlled, double-blind parallel randomised control trial.  
 
To classify the phase of this study is somewhat difficult given esomeprazole is already an 
approved drug. Historically pregnant women and children have been excluded from all phase 1 
trials as they do not fall under the category of “healthy volunteers”. This makes any trial in 
pregnant women more difficult. Furthermore, phase I trials are typical those where the primary 
outcome is safety. There already has been very large cohort studies to suggest 40mg of 
esomeprazole in pregnancy women is safe. 
 
We have classified this trial as a phase 2 trial as we will be assessing efficacy and safety. We aim 
to determine whether esomeprazole is effective for the treatment of pre-eclampsia.  
 
4.2 Study population 
 
Pregnant women diagnosed with early onset pre-eclampsia at a gestational age between 26+0 
weeks to 31+6 weeks who qualify for expectant management. All who consent and meet 
eligibility criteria will be enrolled in the study. 
 
4.3 Intervention 
 
Participants will be randomised to daily administration of either active tablets containing 40 mg 
of esomeprazole or an identical placebo tablet. The study will not alter or interfere with any 
treatment or care given routinely to women with early onset pre-eclampsia. A single dose of 40 
mg will be given orally once a day.  
 
4.4 Sample size calculations 
 
The primary outcome will be to determine whether treatment with esomeprazole can result in a 
gain in length of gestation. 
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In the largest descriptive study on expectant management of early onset pre-eclampsia Hall, et 
al., described the length of gestation gained by such management before delivery44. 
Importantly, this retrospective study was performed at the same hospital where we plan to run 
this trial (Tygerberg Hospital) and clinical practice regarding expectant management is well 
organised, and has not significantly changed since that landmark publication. Thus, it provides 
valuable data with which to base a power calculation for the present study. The reported 
duration that fetuses remained in utero after diagnosis and admission of pregnancies 
complicated by early onset pre-eclampsia was a mean of 11 days (with a standard deviation of 7 
days) and a median 9 days (range of 1 to 47 days)44.  
We believe an intervention that allows a gain in gestation of a further 5 days would be a clinically 
important difference and likely to have important beneficial implications for the fetus (although 
perinatal outcomes will not be a primary outcome in this phase II study).  
 
For 90% power, with a two-sided alpha set of 0.05, 43 patients are required in each group 
(table 1) to identify a gain in gestation of 5 days. Given the data reported by Hall et al was 
skewed, we multiplied this by 1.15 to make a statistical allowance for non-normality45. This 
increases the numbers to 50 per arm (43x1.15). We will add an additional 10 per arm to allow 
for drop-outs, which equates to 60 per arm. Thus, a total of 120 participants will be recruited to 
provide sufficient power to examine our primary outcome. 
Table 1: Sample size calculation 
Detectable difference  
(in days) 
Group size, per arm Group size 
x 1.15* 
3 116 134 
4 66 76 
5 43 50 
6 30 35 
7 23 27 
* The reason for expanding the group size by 15% is that the data in the Hall paper is skewed 
and not normally distributed. The inflation of the sample size by 15% provides an adjustment 
that makes an allowance for non-normality45. 
(Power calculation Performed using PASS 12 software. Hintze, J. (2013). PASS 12. NCSS, LLC. 
Kaysville, Utah, USA) 
 
The gestational age at diagnosis is likely to affect allowable length of pregnancy prolongation. For 
instance, those diagnosed at 31+6 will be delivered at 34 weeks (should they reach that 
Stellenbosch University  https://scholar.sun.ac.za
152 
 
 
gestation), as it is unit policy to deliver at that gestation. Thus, such patients will have a maximum 
length of pregnancy prolongation of 15 days. In contrast, those diagnosed at 28 could conceivably 
obtain many weeks of pregnancy prolongation (if the disease remains stabilised). Further it is 
possible that esomeprazole efficacy may vary with gestational age at diagnosis. 
 
To ensure treatment group allocation is balanced for this potential variable, we will stratify 
randomisation into strata based on gestational age.  
 
 Gestational age (GA) EFW if GA is unknown 
Strata 1 26 +0 up to and including 28+6 
weeks 
Less than and including  1100gm 
Strata 2 29+0 up to and including 31+6 Greater than 1100gm  
 
Stratified randomisation will ensure that the number of participants in each gestational age strata 
is balanced. 
 
4.5 Randomisation and allocation concealment 
 
Randomisation will be done in an equal ratio of esomeprazole to placebo. An online, web-based 
sequence generator system will be used to avoid chance imbalances in the stratification process. 
It will be linked with codes for placebo and treatment tablets provided by the manufacturer 
contracted to produce the trial medication. Researchers and participants will both be blinded. 
 
Randomization will include blocking within each stratum. Blocking ensures that the control and 
treatment group numbers remain close both within the strata and overall. We propose using 
blocks of 4 to 6 with the size and order randomly assigned.  Its use of stratified randomization 
ensures balance between treatment and control groups for gestational age however its use 
induces within stratum induces correlation. We will take this into account in the analysis by 
treating strata as a covariates in regression analysis or as levels in Mantel-Haenszel pooled 
treatment effects. 
 
Once the participants have been randomised the treatment pack with the same code will be 
allocated to the participant. All treatment packs will be identical and will contain either active 
tablets or placebo.  The treatment packs will be prepared by the manufacturer contracted to 
produce the trial medication. The researchers will have no access to the randomisation list.  This 
process will ensure that there is allocation concealment throughout the conduct of the trial. The 
allocation will only be released once the trial is completed. 
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5.0 Inclusion and exclusion criteria 
 
5.1 Definitions: 
 
There are many classification systems for the hypertensive disorders of pregnancy. The 
International Society for the Study of Hypertensive Disorders in Pregnancy (ISSHP) has recently 
published a new classification system for hypertensive disorders in pregnancy46. We will use 
this classification system in this study.  
The following definitions are used in this classification system:  
 
Hypertension in pregnancy: office or in hospital systolic blood pressure greater than or equal to 
140 mmHg and/or a diastolic blood pressure greater than or equal to 90 mmHg on the average 
of at least two measurements, taken at least 15 minutes apart, using the same arm.  
 
Severe Hypertension: systolic blood pressure greater than or equal to 160 mmHg or a diastolic 
blood pressure greater than or equal to 110 mmHg on the average of at least two 
measurements, taken at least 15 minutes apart, using the same arm. 
 
Pre-existing (chronic) hypertension: hypertension that pre-dates the pregnancy or appears 
before 20 weeks gestation. 
 
Gestational Hypertension: hypertension that appears at or after 20 weeks of gestation. 
 
Pre-eclampsia: gestational hypertension and new proteinuria or one or more adverse 
conditions or one or more serious complications (see table 3 for definitions of adverse 
conditions and serious complications). 
 
Adverse condition: consists of maternal symptoms, signs, abnormal laboratory results and 
abnormal fetal monitoring that may herald the development of severe maternal or fetal 
complications. 
 
Significant proteinuria: greater than or equal to 0,3 g/d in a complete 24-hour urine collection 
or a spot (random) urine sample with greater than or equal to 30 mg/mmol urinary creatinine. 
 
Severe pre-eclampsia: pre-eclampsia associated with a severe complication that warrants 
delivery regardless of gestational age. 
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Table 2: ISSHP classification of hypertensive disorders in pregnancy46 
 
 
Table 3: ISSHP classification of adverse conditions and severe complications of preeclampsia39 
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A number of patients seen at Tygerberg Hospital only book after a gestational age of 20 weeks. 
The ISSHP classification systems does not have a class for these patients. We will classify these 
patients according to the classification of Davey and MacGillivray47. 
Unclassified proteinuric hypertension: 
Hypertension and proteinuria diagnosed in a patient who is seen for the first time after 20 weeks 
of gestation.  
 
We will then contact these patients 6 weeks postpartum to determine whether their blood 
pressure has normalized or not and will then retrospectively reclassify them as either as pre-
eclampsia or chronic hypertension with superimposed pre-eclampsia. 
 
5.2 Inclusion criteria 
 
A diagnosis of pre-eclampsia, gestational hypertension with evidence of preeclampsia, 
preexisting hypertension with evidence of pre-eclampsia or unclassified proteinuric hypertension 
has been made by the attending clinician who is of the opinion that the patient and fetus would 
benefit from expectant management. 
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AND all of the following is present: 
• Gestational age between 26 + 0 weeks and 31 + 6 weeks 
• Estimated fetal weight by ultrasound between 500gm and 1800 gm (if gestation is not 
certain) 
• Singleton pregnancy 
• The managing clinicians have made the assessment  to proceed with expectant 
management and that delivery is not expected within 48 hours 
• The managing clinician and neonatologist believe that the fetus could potentially be 
delivered in a  viable condition 
ALSO: 
• No suspicions of a major fetal anomaly or malformation. A major fetal anomaly is 
defined as anomalies or malformations that create significant medical problems for the 
patient or that require specific surgical or medical management. Major anomalies or 
malformations are not considered a variation of the normal spectrum. 
• The mother must be able to understand the information provided, with the use of an 
interpreter if needed 
• The mother must be able to give informed consent 
• Patient will be admitted to hospital for expectant management and standardised care 
 
5.3 Exclusion criteria 
 
• Patient is unable or unwilling to give consent 
• Established fetal compromise that necessitates delivery. This will be decided by the 
clinical team before expectant management is offered to the patient.  
• The presence of any of the following at presentation: 
➢ Eclampsia defined as the new onset of grand mal seizure activity and/or an 
unexplained coma during pregnancy with signs or symptoms of pre-eclampsia48. 
➢ Severe hypertension defined as a systolic blood pressure greater than or equal to  
160 mmHg or diastolic blood pressure greater than or equal to 110 mmHg that 
cannot be controlled with antihypertensive medication within 48 hours of 
admission. 
➢ Cerebrovascular event defined as an ischaemic or haemorrhagic stroke associated 
with clinical symptoms and definitive signs on imaging. 
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➢ Posterior reversible encephalopathy syndrome (PRES) associated with pre-
eclampsia defined on imaging as reversible vasogenic oedema, usually in the 
occipital or parietal lobes. 
➢ Severe renal impairment with a creatinine level of greater or equal to 125 
μmol/l or a need for dialysis. 
➢ Signs of left ventricular failure which include pulmonary oedema requiring 
treatment or oxygen saturations of less than 90% caused by left sided heart 
failure. 
➢ Disseminated intravascular coagulation defined as an INR greater than 2 
➢ Platelet count at presentation less than 50x109 (platelet aggregation excluded) 
➢ Haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome defined 
as a platelet count less than 100 × 109/L, aspartate aminotransferase greater 
than 60 μ/L, and haemolysis as demonstrated by lactate dehydrogenase > 600 
μ/L or haemolysis on a peripheral blood smear or a raised haptoglobin level) 
➢ Liver transaminases greater than or equal to 500IU/L 
➢ Liver haematoma or rupture 
➢ Fetal distress on cardiotocography 
➢ Severe ascites on ultrasound as defined by the sonographer 
• Contra-indications for expectant management of pre-eclampsia 
• Current use of a proton pump inhibitor 
• Contraindications to the use of a proton pump inhibitor 
➢ Previous hypersensitivity reaction to a proton pump inhibitor 
• Current use of a drug that may be affected by a proton pump inhibitor: warfarin, 
ketoconazole, voriconazole, atazanavir, nelfinavir, saquinavir, digoxin, St John’s Wort, 
rifampin, cilostazol, diazepam, tacrolimus, erlotinib, methotrexate and clopidogrel. 
  
Stellenbosch University  https://scholar.sun.ac.za
158 
 
 
6.0 Outcomes 
 
6.1 Primary outcome 
 
Prolongation of gestation measured from the time of enrolment to the time of delivery, in hours 
and days. 
 
6.2 Secondary outcomes 
 
Maternal: 
• (Composite outcome) The occurrence of any of the following serious maternal outcomes:  
➢ Maternal death 
➢ Eclampsia 
➢ Pulmonary oedema (oxygen saturation ≤90%, with clinical signs and symptoms 
requiring treatment) 
➢ Severe renal impairment or the need for dialysis 
➢ Cerebral vascular event 
➢ Liver haematoma or rupture 
 
• Other maternal outcomes, where all of the following will be compared as individual 
outcomes: 
➢ Admission to a high care or intensive care unit 
➢ Posterior reversible encephalopathy syndrome (diagnosed on imaging) 
➢ Left ventricular failure (diagnosed on echocardiography) 
➢ Serum creatinine greater than or equal to 125 μmol/l 
➢ Proteinuria greater than or equal to 3g/24h 
➢ Hypertension with a systolic blood pressure greater than 160mmHg or a diastolic 
blood pressure greater than 110mmHg despite anti-hypertensive treatment 
➢ Disseminated intravascular coagulation  
➢ Platelet count less than 50x109 
➢ Haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome defined as a 
platelet count less than 100 × 109/L, aspartate aminotransferase greater than 60 μ/L, 
and haemolysis as demonstrated by lactate dehydrogenase greater than or equal to 
600 μ/L or haemolysis on a peripheral blood smear or a raised haptoglobin level) 
➢ Liver transaminases >500IU/L 
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➢ Placental abruption defined as a retroplacental clot covering more than 15% of the 
maternal surface or a diagnosis on histology 
➢ Mode of delivery  
➢ Use of antihypertensive agents (number of agents and daily dose at delivery) 
➢ Major postpartum haemorrhage (defined as blood loss of more than 1000mls in 24 
hours) 
➢ Thromboembolic disease (defined as a deep-vein thrombosis , pulmonary embolism 
or both) 
➢ Moderate or severe ascites noted on ultrasound or at delivery 
 
Fetal: 
(Composite outcome) The occurrence of any of the following serious fetal outcomes:  
➢ Reversed a-wave in the ductus venosus on fetal ultrasound 
➢ Significant changes in heart rate patterns on the non-stress test or cardiotocograph, 
as defined by the attending clinician, that necessitate delivery 
➢ Intrauterine fetal demise 
➢ Incidence of fetal growth restriction at birth as defined by growth charts based on the 
local population 
➢ Persistent reversed flow in the umbilical artery confirmed on two fetal ultrasounds 
➢ Redistribution in the middle cerebral artery 
There is no standard classification system for the non-stress test. The attending clinician usually 
assess the heart rate patterns by looking at the baseline, assessing for baseline shifts, by assessing 
the variability, by looking at the presence or absence of accelerations and the presence of 
decelerations and by assessing for a sinusoidal pattern. The gestational age of the fetus is also 
taken into consideration when assessing the non-stress test. The Royal College of Obstetricians 
and Gynaecologists Evidence-based Clinical guideline Number 8 on electronic monitoring is 
routinely used at Tygerberg hospital for and will be used by the attending clinician to assess the 
cardiotocograph. (www.nice.org.uk/nicemedia/pdf/efmguidelinercog.pdf) 
 
Neonatal: 
Composite outcome) The occurrence of any of the following serious neonatal outcomes:  
➢ Neonatal death within 6 weeks after the due date 
➢ Grade III or IV intraventricular haemorrhage defined on imaging as enlarged ventricles 
associated with haemorrhage or when the haemorrhage extends into the cerebral tissue 
around the ventricles 
➢ Necrotizing enterocolitis diagnosed on radiographic studies 
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➢ Bronchopulmonary dysplasia defined as needing oxygen at day 28 of life, either on a 
ventilator, by  CPAP or via a nasal catheter and significant neonatal sepsis as defined by 
the attending paediatrician. 
 
Other neonatal outcomes, where all of the following will be compared as individual outcomes: 
➢ APGAR score of less than 7 at 5 minutes 
➢ Umbilical artery pH below 7.05 
➢ Umbilical artery lactate 
➢ Surfactant use 
➢ Neonatal intensive care admission or special care unit admission 
➢ Intubation and mechanical ventilation or continuous positive airway pressure (CPAP) 
support 
➢ Grade III/IV hyaline membrane disease 
➢ Length of oxygen treatment 
➢ Hospital stay 
➢ Incidence of retinopathy of prematurity 
➢ Early neonatal sepsis (Haematological infection diagnosed on blood culture with 
associated clinical findings or as defined by attending paediatrician) 
 
Biomarkers: 
 
We will ship the following samples from Tygerberg Hospital to The Mercy Hospital, where the 
following assays will be done (by researchers blinded to clinical groupings) in the Translational 
Obstetrics Laboratory at Melbourne University if consent has been given by the mother.  
 
• Maternal plasma samples: sFlt1, sEng, endothelin 1 and esomeprazole levels. 
• Placental samples: mRNA and protein expression of HO-1, sFlt1 and endothelin 1.  
• Immunohistochemistry will be also performed for these same molecules. 
• Umbilical cord plasma obtained delivery:  esomeprazole levels. 
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7.0 Trial conduct 
 
7.1 Identification and enrolment of participants 
 
7.1.1 Identification 
 
Potential participants will be identified after they have been admitted to Tygerberg Hospital 
(tertiary referral centre) with a diagnosis of early onset pre-eclampsia. The clinical management 
team will decide if the patient qualifies for expectant management and is suitable for admission 
as per the hospital protocol (potentially can be recruited), or delivery is likely to be imminent 
within 48 hours (exclusion criteria). The research midwife and principal investigator will be 
notified by the ward staff and/or clinical treating team. 
 
Normal clinical care will be maintained throughout the study.  The use of steroids and magnesium 
sulphate will be according to local protocols and will be decided upon by the managing clinician. 
The use of aspirin and calcium will be noted. 
 
Inclusion and exclusion criteria will be assessed before approaching the patient. 
 
7.1.2 Consent 
 
Information about the trial will be given to the patient and a translator (working from a script) 
will be used if necessary. Information sheets and study details will be given to the patient and 
any questions about the study will be answered. A translator will be used so the patient will have 
the opportunity to go through the information in their own language. If they would like to be 
involved in the study they will be asked to provide written informed consent. The consent form 
will be made available on self-duplicating paper in order that a signed copy can be given to the 
participant, a copy can be put in the clinical notes and a copy kept by the study investigators. The 
consent forms will be translated into English, Afrikaans and Xhosa. Only the study investigators 
and research midwives will be able to take consent. The patient will be given as much time as 
they need to decide whether they would like to be involved. Once the participant has signed 
consent they will be enrolled in the study. 
 
7.1.3 Recruitment 
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Once the eligibility criteria have been checked and the informed consent document has been 
signed we will obtain the following: 
• Baseline clinical information regarding the pregnancy (maternal age, parity, obstetric 
history, antenatal history, medical history, drug history, allergies, smoking status, alcohol 
and drug intake) 
• Baseline information 
- Degree of proteinuria (24 hour protein excretion) 
- Maternal assessment (renal function, liver function, blood count) 
- Fetal assessment with ultrasound (biometry, estimated fetal weight, Doppler and 
amniotic fluid index findings) 
 
7.2 Study treatment 
 
5.2.1 Trial drug 
 
After randomisation an individual treatment pack will be allocated to the participant according 
to an online web-based randomisation process. The participant will be allocated an individual 
trial number. The participant’s name and trial number will be written on the pack. The packs will 
be identical in shape, colour, weight and feel. Each pack will contain proton pump inhibitor 
tablets or identical placebo tablets.  
 
7.2.2 Packaging, formulation and supply of the treatment 
 
The trial drug and placebo will be produced by a contracted manufacturer IDT pharmaceuticals 
(http://en.idtaus.com.au). The trial drugs will be placed into containers and labelled randomly according 
to the computer generated randomisation list. Labelling, storage and preparation will be done according 
to the requirements of the Medicines for Human Use (Clinical Trials) regulations. The placebo will 
undergo a placebo analysis before the trial is started to confirm the contents. 
 
7.2.3 Route of administration, dosage regimen and treatment period 
 
Each participant will be given a treatment pack. The treatment pack will contain treatment for 
21 days.  A single capsule will be taken, once daily one hour before meals (if the patient is eating). 
On the first day of randomisation the first dose will be taken in the evening. Treatment will then 
be taken daily in the evening until the pregnancy has ended. Trial drugs will be kept in the 
packaging they are provided in and under no circumstances will it be used for other participants.  
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The trial medication will be written up on the treatment chart and the chart will be signed by the 
nursing staff to confirm that the participant has taken the medication and to confirm compliance. 
The research midwife will monitor the treatment chart to assure compliance. As a second 
compliance check the patient will be asked return the empty packaging to the research midwife 
who will record the number of empty tablet containers at the time of delivery of the patient. 
 
7.2.4 Resupply of treatment 
 
It is assumed that for most patients, delivery will occur within 21 days of randomisation. However 
in some cases delivery may occur after 21 days of randomisation. In these cases continuation trial 
drug packs will be available. In these cases the principal investigator will contact the 
randomisation office and ask for a number for a continuation pack.  The continuation pack will 
be matched to the contents of the initial treatment pack and will contain a further 21 day supply 
of the treatment. 
 
7.3 Expectant management for pre-eclampsia 
 
7.3.1 Routine management 
 
Expectant management for early onset pre-eclampsia involves admission to hospital, and close 
maternal and fetal surveillance.  
 
Maternal surveillance includes four hourly blood pressure measurement, twice daily clinical 
assessment, daily urinalysis, and twice weekly assessments with blood tests (full blood count, 
renal function tests and hepatocellular enzymes if HELLP syndrome is suspected) and 24 hour 
urinary protein measurement on admission. 
 
Fetal surveillance includes six-hourly cardiotocography and ultrasound assessments every two 
weeks (or more frequently if clinically indicated) for Doppler velocimetry of the umbilical artery, 
middle cerebral artery, ductus venosus, amniotic fluid volume assessment and growth. 
 
All participants will receive two doses of betamethasone 24 hours apart to reduce the risks of 
neonatal respiratory distress syndrome, intracranial haemorrhage and necrotising enterocolitis. 
A single repeat dose is usually given one week later.  
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Most participants will be on antihypertensive treatment and the medication used will be 
documented. All women should already be receiving iron and folic acid supplementation. 
 
Clinical care will be left up to the discretion of the clinical team. The indication for delivery will 
be a clinical decision. Indications for delivery may include failure to control blood pressure, the 
development of major maternal or fetal complications, or intrauterine fetal death.  Expectant 
management will usually end at a gestation of 34 weeks. 
 
7.4 Clinical Follow-up 
 
7.4.1 Baseline clinical information 
 
Baseline clinical information collected will include maternal age, gravidity and parity, gestation, 
obstetric history, antenatal history, medical and surgical history, medication history, allergies, 
smoking status, alcohol and drug intake, height, weight and body mass index. A photocopy of the 
antenatal notes will be made and stored with the data capture sheets. 
 
Ongoing clinical data will be collected daily on data capture sheets. This will include clinical 
measurements, medications, haematological parameters, biochemical parameters, fetal 
ultrasound and fetal heart rate assessments. Patient folders will be reviewed after delivery to 
confirm that the data collected is complete and accurate. Once the patient has delivered the 
folder will be photocopied to assure that all the data is recorded. 
 
7.5 Sample collection 
 
7.5.1 Blood samples 
 
Blood samples are taken as part of routine clinical care (twice a week). These include 
measurements of the haemoglobin, the platelet count and the urea and creatinine levels. If HELLP 
syndrome is suspected the hepatocellular enzymes are measured and a coagulation profile may 
be ordered. We will collect an extra 9 mls of blood each time routine bloods are taken to obtain 
plasma samples. These will be processed immediately and frozen at -80°C for later analysis of 
sFlt, sEng, and endothelin 1. In addition, all participants we undergo the following test once: we 
will precisely time blood sampling 2 hours after taking the trial medication where we will measure 
plasma esomeprazole levels. 
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Tubes will be labelled with the participant’s trial number and folder number. The samples will be 
spun, and split into two aliquots. One aliquot will be used to measure sFlt-1 and sEng. The 
laboratory doing the measurement of sFlt-1 and s-Eng will be confirmed closer to the start of the 
trial.  The other aliquot will be stored in a -80 degree freezer and sent to Melbourne University 
for analysis and will be analysed in the Translational Obstetrics Laboratory.  
 
We plan to measure the following in the blood samples: 
 
o Biomarkers of endothelial injury: endothelin 1 and inflammatory cytokines 
o Antiangiogenic factors associated with pre-eclampsia: sFlt1 and soluble endoglin 
o Esomeprazole levels in the blood 
o The samples sent to Melbourne may be used to measure other relevant analytes 
associated with pre-eclampsia. No genetic testing will be performed on these samples.  
 
The purpose of these blood analyses is to have more objective (and scientifically robust) evidence 
of maternal disease regression than the clinical and routine laboratory indicators described 
above. We hypothesise these biomarkers (particularly sFlt1 and soluble endoglin) will be 
significantly lower among the group given esomeprazole. 
 
7.5.2 Urine samples 
 
Urine samples will be collected 2 times per week and sent for spot protein: creatinine ratios. 24-
hour protein excretion is routinely measured only once on admission. For the purposes of this 
study we will repeat it weekly. This will be performed at the Tygerberg Laboratory. 
 
7.5.3 Cord Blood Samples 
 
Cord Blood Samples will be collected at delivery and will be labelled with the participant’s trial 
number and folder number. These samples will also be stored and sent to the University of 
Melbourne for further analyses where they will be analysed in the Translational Obstetrics 
Laboratory. We plan to measure esomeprazole levels in the cord blood obtained at the time of 
the delivery. 
 
7.5.4 Placental samples 
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Placental samples will be collected at delivery from women who have consented for this to be 
performed. We will take three 1cm3 full thickness biopsies of the placenta. Each sample will be 
frozen and stored in -80 degree freezer within a PIE Trial storage box. A further sample will be 
collected and fixed in formalin. 
 
We plan to measure the following in the placental samples: 
 
o Expression of heme-oxygenase-1 (both mRNA and protein levels) 
o Expression of anti-angiogenic factors in the placentas 
o Perform a microarray to examine the mRNA expression of key anti-oxidant and hypoxia 
pathways. 
o Antiangiogenic factors associated with pre-eclampsia: sFlt1 and soluble Endoglin 
o Immunohistochemistry 
 
In addition, we plan to store remaining samples to measure other relevant analytes that may yet 
be discovered in relation to pre-eclampsia. We will not perform any genetic testing on these 
samples. These tests will be done in the Translational Laboratory at Melbourne University. 
 
7.6 Withdrawal from the study 
 
All participants will be informed that they are free to withdraw from the study at any time, and 
that this will not affect their clinical care. In the event of a withdrawal, we will ask whether we 
can still collect clinical data and include them in our analyses. 
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8.0 Data management and statistical analysis 
 
8.1 Data management 
 
Data will be collected prospectively by the researchers and data checking and entry of the 
completed data collection forms will be reviewed. Duplicate copies of original data collection 
forms will be used for quality control purposes. 
 
8.2 Data recording  
 
Data will be collected on data capture sheets will be transcribed onto a Microsoft Excel 
spreadsheet. Only the participant number will be entered onto the spreadsheets. Data cleaning 
will be performed on an ongoing basis and again at the end of the study.  
 
8.3 Handling of missing data 
 
If data is missing the original data extraction sheets will be reviewed and if needed the original 
patient notes will be reviewed. 
 
8.4 Data processing 
Data entry and checking will be continuous, and queries will be followed vigorously to ensure 
clarification without delay. 
 
8.5 Analysis plan 
The analyses will be on an intention-to-treat principle with comparisons made between proton 
pump inhibitors and placebo, for primary and secondary outcomes.  Comparisons will be 
expressed as relative risks or mean differences with 95% confidence intervals.   
 
8.6 Statistical methods 
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The patient characteristics, by treatment group, will be presented as mean (SD), median [25th – 
75th percentile], minimum, maximum and count (%) depending upon type and distribution. 
Significance level is set at 0.05 and all hypothesis testing will be two-sided.  
 
The primary outcome will not be adjusted for multiple comparisons but the secondary outcomes 
will be adjusted for multiple comparisons using a small number of pre-specified outcomes. 
 
Primary outcome 
 
We plan to perform two analyses: 1) primary intention to treat analysis (ITT) and 2) a treatment 
received (TR) analysis to examine response among those who actually took the tablets. The 
primary outcome (prolongation in days) between treatment groups will be tested using ANCOVA 
regression analysis with both treatment group and gestational strata as covariates.  
 
We will present results as mean group difference with 95% confidence intervals (95%CI). 
Standard regression diagnostics will be performed and transformation of primary outcome, to 
achieve adequate distributions of residuals, if indicated. We will also present survival analyses 
(ie time until delivery), using Cox proportional hazards regression and Kaplan-Meier 
survivorship curves. 
 
Secondary Outcomes 
 
For these composite outcomes or single outcomes, continuous variables will be compared using 
either T-test (for normally distributed variables) or Mann-Whitney U (non-normally distributed). 
Categorical values will be compared using chi-squared test. For the longitudinal data of plasma 
sFlt-1, sEng and endothelin 1 levels, we will 1) graph the data longitudinally 2) compare levels 
between the groups relative to gestational age 3) compare levels between groups relative to 
days after recruitment and 4) compare levels between groups at delivery. 
 
The various maternal and fetal outcomes will be compared as either composite outcomes or as 
single variables, listed as per 6.2. Continuous variables will be compared using either T-test (for 
normally distributed variables) or Mann-Whitney U (non-normally distributed). Categorical 
values will be compared using chi-squared test. 
 
The same approach will be used to compare circulating sFlt-1, sEng or other molecules/variables 
measured subsequently in the laboratory. 
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9.0 Safety and Monitoring procedures 
 
9.1 Adverse event 
 
All Adverse events will be documented and reported. An adverse event includes 
• Any unintentional, unfavourable clinical signs or symptoms. This includes complications 
of pre-eclampsia. 
• Any new illness or disease or the deterioration of existing disease or illness. 
• Any clinically relevant deterioration in any laboratory or clinical tests. 
These events will be recorded on the daily data capture sheets. 
 
The following are not considered adverse effects: 
• A pre-existing condition (unless it worsens significantly in pregnancy over and above what 
may be expected with the concurrent diagnosis of pre-eclampsia). 
• Diagnostic or therapeutic procedures such as surgery. 
 
9.2 Serious adverse event 
 
Serious adverse events include any of the following 
• Maternal or fetal death. 
• Threat to the life of the mother or baby. 
• Event that results in a longer post-natal hospital stay. 
• Event that results in a persistent or significant disability in the mother. 
• Congenital or birth defect in the baby that is detected in the post-natal period and was 
not detected on ultrasound. 
  
9.3 Expected serious adverse events 
 
Certain serious adverse events will be expected as we are treating women with early onset pre-
eclampsia with premature fetuses. We will expect to have serious adverse events related to the 
diagnosis of pre-eclampsia which include severe hypertension, intracranial haemorrhage, renal 
failure, abnormal hepatic function, disseminated intravascular coagulopathy, eclampsia, left 
ventricular failure, pulmonary oedema and haemorrhage. Complications of prematurity that may 
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be expected include sepsis, necrotising enterocolitis, respiratory complications, seizures, 
hypoglycaemia and intra-ventricular haemorrhage. 
 
All serious adverse events will be reported to the principal investigator (or other nominated 
clinician) as soon as they have been identified. Full details including the diagnosis (if possible), 
the duration, actions taken, treatment given, outcome, causality and whether the event is 
expected or unexpected will be reported. A serious adverse event document will be completed 
and this will be sent to the data monitoring committee as soon as physically possible. The report 
will be emailed to the committee.  
 
If an event is considered potentially related to the trial medication (and not in keeping with pre-
eclampsia) it will then be immediately reported to the data monitoring committee and the 
manufacturer. Reporting and handling of adverse events will be in accordance with the GCP 
guidelines49. These procedures have been used in previous multicentre trials and proven to be 
efficient and compliant with the GCP principles and data management49. 
 
9.4 Unblinding 
The need for unblinding should be very uncommon as the trial intervention is rarely associated 
with severe side effects and it will not delay or prevent standard management of the patient. If, 
however, unblinding is needed for any reason the principal investigator will be informed and, if 
necessary, the treatment will be revealed.  Sheets with lists of 50 randomisation codes each will 
be sealed in individual, signed, numbered envelopes.  If unblinding is requested, the relevant 
envelope will be opened by a person not involved in the trial in the presence of two witnesses, 
the group allocation read, and the list re-sealed in an envelope and signed.  The randomisation 
envelopes will be accessible at all times to the principle investigator who will be contactable by 
mobile telephone. The principal investigator will co-ordinate the above process. 
 
 
9.5 Reasons to stop the trial 
If for any reason, there is a need to stop the trial prematurely this decision will be taken by the 
Data and Safety Monitoring committee. 
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10. Duration of the project 
 
It is anticipated that the study can be completed in approximately 4 years (2015 – 2018).  The 
duration of the study has been approximated using data from the study by Hall et al., who 
studied expectant management of pre-eclampsia in the same group of patients in the same 
hospital. They averaged 56 patients per year and the cohort was obtained from 1992 to 1997. 
Since then deliveries at Tygerberg hospital have increased substantially. In the past year at 
Tygerberg Hospital it is estimated that 146 women were expectantly managed with early onset 
pre-eclampsia. If we were able to randomise half of these women we would be able to recruit 
73 per year. We would then be able to recruit 120 women over a two to three year period, but 
have decided to plan for a four year period in case the numbers are less than expected. 
 
The recruitment will begin as soon as we have approval from Human Research Ethics and the 
South African Medicines Control Council and Tygerberg Hospital. This study has been registered 
with NHREC (South African Human Research Ethics Committee) and PACTR (Pan African Clinical 
Trials Registry). We anticipate that this process will require six to nine months. 
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11. Project management 
 
The trial coordination and management will be done by the principal investigator (PI Cluver) in 
South Africa. The trial management will include coordination and execution of the following 
activities which require administrative and clinical research input. 
 
11.1 Quality control procedures 
 
Before recruitment 
 
A trial pilot run on recruitment, trial procedures, data collection and sample collection will be 
done before the study starts.  
 
During recruitment 
 
1. Data checking and entry of the completed data collection forms will be continuous.  All data 
will be double entered from the trial data sheets, cleaned and queries checked immediately. Data 
sheets and all other documents will be stored for future reference, audits and queries in a secure 
location.  
2. Double-blinding with identical-looking placebos will avoid any biases at entry to the trial and 
during the monitoring of women and assessment of outcomes, with respect to the main 
comparison.  
3. Randomisation will occur after informed consent has been given.  If a treatment pack is not 
used for whatever reason, it will be retained unopened with the woman's name on it. The woman 
will remain in the trial and all data collected and reported on an ‘intention to treat’ basis. The 
used and unused packs will be kept in the centres until completion of the trial and any quality 
assurance checks thought necessary. 
4. Good Clinical Practice (GCP) procedures (WHO 1995) will be followed. 
5. A random sample of unused packs will be tested for content to ascertain whether the content 
matches coding.   
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After recruitment 
 
Data will be analysed and reported on an intention-to-treat basis.  The draft analysis plan will be 
finalised before recruitment starts.  The trial report will include requirements laid out in the 
CONSORT statement (Begg et al 1996). 
 
Follow-up procedures 
 
All participants will be followed from enrolment until their discharge from hospital after delivery 
and all data will be recorded. 
 
 
11.2 Trial committee 
 
Data Monitoring Committee 
 
The Data Monitoring Committee will have meetings four times per year to discuss the progress 
of the trial. They will be supplied with reports of progress every three months. They will be 
notified as per the protocol of all serious adverse effects. If there are serious concerns they will 
arrange an emergency meeting and they will be able to stop the trial at any time. Minutes of their 
meetings will be sent to the chair of the PIE Steering Committee for documentation and auditing 
purposes. 
 
11.3 Preparation for the trial 
 
Coordination activities 
 
• Investigator meeting before recruitment: standardisation of trial procedures; reception, 
handling and storing of trial materials; recruitment rate 
• Discussion of logistics of treatment administration 
• Establish communication procedures 
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• Designation of Data Monitoring Committee 
• Organization of initial and final collaborators meetings 
 
Trial materials 
 
• Preparation of data collection forms and consent forms 
• Preparation of trial manuals 
• Preparation of the boxes for the treatment packs and their contents 
 
Data processing and system preparation 
 
• Randomisation of subjects 
• System set-up for data entry and validation  
• System set-up for production of monitoring reports  
 
Statistical issues 
 
• Preparation of dummy tables 
• Definition of monitoring reports to be produced 
 
11.4 Conduct of the trial 
 
Coordination activities 
 
• Monitor trial progress 
• Communication with the data monitoring committee 
 
Data management and statistical analysis  
 
• Data entry 
• Data validation and production of queries 
• Update of the master file using batches of new data or corrections coming from validation 
checks and/or answers to queries 
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• Monitoring reports: recruitment, adverse events, losses to follow-up, completeness of data 
for main outcomes 
 
Administrative 
 
• Assistance with the organization of trial-related meetings including travel arrangements 
• Maintaining a mailing list of trial contacts (collaborators and data monitoring committee 
members) 
• Posting, photocopying, faxing 
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12. Ethical aspects 
 
12.1 Confidentiality  
 
Participant confidentiality will be maintained throughout the course of the study.  Only on-site 
study staff will have access to the data.  In order to protect participant confidentiality, each 
participant will be assigned a unique Participant Identification number (Participant ID). Patient 
confidentiality will be protected according to the regulations set forth by Stellenbosch 
University’s Human Research Ethics Committee or Institutional Review Board (IRB).  Biological 
samples that are collected will only be identified with the folder number and participant’s trial 
number. Laboratory staff will not have access to the personal data. 
 
All personal data on paper format will be stored in a secure location and will be treated as strictly 
confidential. No data that could identify a participant will be released. 
 
All data collected will be stored for a minimum of 5 years or longer as defined by the 
requirements of the Ethics Committee once the trial is completed. 
 
12.2 Compensation for participation 
 
There will be no compensation for participation in this trial and treatment will be no different 
to standard care. 
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13. Potential risks and benefits of the study  
 
This study aims to find a treatment for early onset pre-eclampsia. If a treatment is found it could 
decrease both maternal and neonatal morbidity and mortality rates. If the drug was able to 
prolong gestation for women suffering from early onset pre-eclampsia it would enable them to 
deliver a healthier baby and would decrease the work load considerably for the neonatal services. 
 
Proton pump inhibitors have been used in pregnancy and the chance of maternal or fetal effects 
is likely to be very small. 
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14. Resources and strengths of the study 
 
14.1 Strengths of our study 
 
1) Incidence of early onset pre-eclampsia is extremely high in South Africa: For reasons that are 
unknown the rates of early onset pre-eclampsia (and eclampsia) are higher in the developing 
world. Duley, for instance, reported the incidence of eclampsia in the developed world is 2-
3/10,000, but 16-69/10,000 in the developing world (ie 8-30 fold increase)50. Audit data on the 
number of cases of early onset pre-eclampsia managed at Tygerberg Hospital suggests that this 
trial can be feasibly performed in just one hospital. In stark contrast with the incidence of early 
onset, pre-eclampsia in the developed world being ≤1%, a number of recruiting sites would be 
needed in first world countries. As an example the STAMP trial (assessing the treatment of early 
onset pre-eclampsia with pravastatin) aims to recruit 120 women in the UK. They have over 15 
recruiting sites. Currently the two external supervisors (Prof Stephen Tong and Prof Susan 
Walker) are running a pilot trial in Australia on the use of pravastatin for the treatment of early 
onset pre-eclampsia. Pravastatin is a category D/X drug. In South Africa we will be using a class 
C drug. 
2) Running the trial at Tygerberg Hospital will make the findings relevant globally: Tygerberg 
Hospital has many modern state of the art facilitates on par with tertiary referral hospitals in 
the developed world. We have a neonatal special care unit, a maternal high dependency unit 
and an academic centre that actively contributes to the global scientific literature. Thus, 
running this study here has the dual advantages of: 1) having large numbers of early onset pre-
eclampsia seen only in the developing world and 2) a centre that practises modern obstetrics 
similar to that in the developed world.  
 
3) It capitalises on a unique collaborative opportunity between Australia and South Africa: Dr 
Catherine Cluver is an academic clinician based at Tygerberg, South Africa. In 2013, she was the 
visiting maternal-fetal medicine Fellow at Mercy Hospital (where Prof Walker and Prof Stephen 
Tong are based). A close clinical and academic collaboration developed among the CIs who have 
worked together to generate this trial protocol.  
 
14.2 Limitations of this study: 
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This study is powered to identify a prolongation of pregnancy of five days, and is underpowered 
to detect benefits such as a shorter (but still beneficial) prolongation of pregnancy. It is not 
powered to determine differences in significant maternal outcomes or neonatal benefits. 
 
If esomeprazole does prove to be effective we would then proceed to a larger multicentre study 
which would be better powered to investigate these outcomes. 
 
Furthermore, while this study may provide immense value in the developing world, it is possible 
any positive findings would need to be confirmed in the developed world before it is considered 
globally relevant. 
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15. Publication of results 
 
We will publish the results of this trial (whether or not we prove our hypothesis) in publically 
accessible, peer reviewed journals. If we obtain a positive finding, it is possible the findings could 
be published in a high impact journal and could change clinical practice. 
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16. Appendices 
 
Consent form 
Patient information sheet  
Trial schema flow chart 
Budget 
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PATIENT INFORMATION LEAFLET: 
PIE TRIAL 
 
 
SUMMARY 
 
Name of principal investigator: Dr Cathy Cluver 
 
Name of research midwife: …………………….. 
 
Contact number: ………………………………… 
 
Website: …………………………………………. 
 
What is pre-eclampsia? 
Pre-eclampsia is a serious condition that is only found in pregnancy. 
It is associated with high blood pressure and can affect different parts of your body like the 
kidneys. 
At present there is no effective treatment for pre-eclampsia except for birth of your baby but 
premature birth may cause medical problems for the baby. 
For this reason we will keep you in hospital to monitor your pregnancy and health so that we 
can try and safely prolong your pregnancy to prevent your baby from possibly suffering some of 
the complications of a premature birth. This is the normal care that all women with early pre-
eclampsia have. 
 
The trial: 
You are being invited to participate in a clinical trial that may help with finding a treatment for 
pre-eclampsia. This trial is to determine whether esomeprazole (a medication that is commonly 
used for reflux) can treat pre-eclampsia. This treatment may or may not improve your condition 
and may or may not delay the need for your baby to be born prematurely. This medication is 
safe in pregnancy and has been used by many pregnant patients. 
 
If you decide to take part in the trial you may be given esomeprazole tablets or you may be 
given a placebo (dummy) tablet. You, the doctors and the nurses will not know what treatment 
you are being given. There is a 1 in 2 chance that you will be given the placebo or the 
esomeprazole tablet. Both tablets will look identical. Everyone in the study will receive exactly 
the same treatment as patients that are not in the study. If you are involved in the study you 
may have extra ultrasounds and we may need to collect extra blood from you while pregnant 
and at delivery a sample of blood from the cord and part of the placenta when you deliver. 
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If you would like to be involved in the clinical trial it will be important to start the medication as 
soon as possible. If you have any further questions about the study you can ask us questions at 
any time and we can be contacted on the telephone numbers given above. 
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BACKGROUND INFORMATION ON  
PRE-ECLAMPSIA 
 
What is pre-eclampsia? 
 
Pre-eclampsia is a serious medical condition that affects only pregnant women. It is caused by 
products released from the placenta that cause the mother to then suffer from high blood 
pressure. It commonly also effects the kidneys and this is seen by measuring the amount of 
protein in the urine. Pre-eclampsia can affect other organs in the body and can cause liver 
problems, blood clotting problems, and in severe cases seizures and stroke. 
 
How do we treat pre-eclampsia? 
 
At present there is no known treatment for this condition apart from delivery of the baby and 
the placenta. Early delivery can be associated with medical problems for the baby. Babies that 
are born too early can suffer from breathing problems, problems with their intestines and can 
have bleeding in the brain. We know that every day in early pregnancy can make a difference to 
the babies’ survival and for this reason we admit pregnant mothers with this condition early in 
pregnancy to the hospital. Many studies have shown that this is a safe form of management as 
long as mothers are monitored very closely in the hospital. 
 
When will I have my baby? 
 
When you reach 34 weeks we will consider delivering the baby as we know that most babies 
born at this age do well. If you develop any complications or if the baby is in distress we will 
deliver your baby before we reach 34 weeks. 
 
What treatment will I receive? 
 
During your stay in hospital we will be monitoring your blood pressure. We will be checking 
your urine everyday to see how much protein you are losing through the kidneys. Twice a week 
we will be doing blood tests to monitor for complications. A doctor will be seeing you every day 
to check you and your baby’s health. Every week there will be a large number of doctors that 
come and do a ward round to make sure that you and your baby are well. Your baby will be 
monitored 4 times a day with a monitor on your tummy. Ultrasound examinations of your baby 
will be performed. 
 
You will receive treatment to control your blood pressure if it is needed and we may prescribe 
some pregnancy vitamins and supplementations. If you loose a large amount of protein in your 
urine you may be started on a treatment to prevent blood clots.  
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INVITATION TO BE INVOLVED IN THE PIE TRIAL 
 
You are being invited to participate in a research project to find out whether a drug called 
esomeprazole can be used to treat pre-eclampsia. The name of the study is the Pre-eclampsia 
Intervention with Esomeprazole (PIE) trial. It is important that you read all the information 
provided about the trial before you decide to take part and that you understand why we are 
doing the research and what you would need to do if you were involved in the study. If you 
have any questions about the trial you can ask your doctor, the midwives or any of the staff 
from the research project. You can talk to any of the other women who have decided to be 
involved or not involved in the study. 
 
Why are we doing this study? 
 
Pre-eclampsia is a dangerous condition in pregnancy. If we could find a treatment for pre-
eclampsia we would possibly be able to save many pregnant mothers and babies. There is no 
known treatment for pre-eclampsia. Other researchers in England are doing studies with a drug 
called pravastatin but have not finished their study yet. 
 
What is the purpose of this study? 
 
Recent research has shown that there are substances produced by the placenta that can cause 
pre-eclampsia. Work done in a laboratory in Melbourne, Australia has shown that these 
substances may be reduced by the group of drugs called proton pump inhibitors. Esomeprazole 
is one of these drugs. The PIE trial is the first trial in the world that will look to see if 
esomeprazole can be used to treat pre-eclampsia. 
 
Why have I been invited to be involved in this study? 
 
You have been invited to be in this study as you have been diagnosed with pre-eclampsia. We 
would like to include 120 women with pre-eclampsia in this study. 
 
Do I have to be in the study? 
 
It is voluntary to be in the study and it is your choice to be involved or to not be involved. Your 
treatment will not be any different if you are not involved in the study. You can decide at any 
stage in the pregnancy to withdraw from the study and you will not have to give a reason for 
why you want to withdraw.  
 
Will I need to do anything extra if I am in the study? 
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Once you have decided to be in the trial you will need to sign an informed consent document. 
This form will say that you want to be involved in the study and that you have read and 
understood the information we have given you about the trial. 
 
You will then need to take one extra tablet in the evening before you go to bed until the baby is 
delivered. One of the research team will visit you every day to see how you are feeling and to 
collect information about your pregnancy. When your routine blood tests are done we will take 
an extra sample of blood for the study. On the first day that you take the medication we will 
need to take an extra sample of blood. We may need to do extra ultrasound examinations of 
your baby. Once your baby is born and the cord has been cut we will take a small amount of 
blood from the placenta. We will take a small sample from the placenta which will be sent for 
testing. We will follow you up after the delivery of the baby. The samples taken may be sent 
overseas for further testing to try to find a treatment for pre-eclampsia. Only tests related to 
finding a cure for pre-eclampsia will be performed on the samples taken. 
 
Is esomeprazole treatment safe in pregnancy? 
 
Esomeprazole is used in pregnancy to treat reflux and gastric ulcers. There have been no 
reports of fetal problems in humans or complications in human pregnancies caused by this 
medication or other medications in the same class of drug. 
 
Are there any side effects of esomeprazole? 
 
All drugs may have side effects. Side effects that have been associated with the use of 
esomeprazole include headache, diarrhea, abdominal pain, constipation and a dry mouth. 
There are certain drugs that cannot be used with esomeprazole. If you are taking one of these 
drugs you will not be asked to participate in the trial. We will provide you with a copy of the 
product information leaflet if you would like more information. 
 
Will I receive the placebo treatment or the esomeprazole treatment? 
 
We will not know until the study is completed whether you were taking the dummy/placebo 
tablet or the esomeprazole tablet. The tablets will look identical and the midwives, nurses and 
doctors will not know which tablet you are taking. The tablet packages will be the same and 
only the pharmacy organizing the tablets will know what is in each packet. Once the study is 
completed we will then find out what tablets you were taking. 
 
What will happen to the blood samples and the samples taken from the placenta? 
 
These samples will be stored and may be sent to a laboratory at Melbourne University, 
Australia. The laboratory staff may do tests to see if esomeprazole can be used to treat pre-
eclampsia. Only tests related to pre-eclampsia will be done on the samples. Your samples will 
not be used for genetic testing. 
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Will my information be kept confidential? 
 
All information collected in the study will be kept strictly confidential. Information collected will 
only be available to people directly involved in the study. Your information will be given a study 
number and your name will not be used for identifying any of your samples. The data collected 
will be locked in a secure location and only people involved in the study will have access to this 
information. Your name will not appear on any presentations or publications relating to this 
study. Only your study number will be on the samples taken and none of the laboratory staff 
will have access to your name or contact details. 
  
Are there any benefits of me for being involved with this study? 
 
Only half of the women in this trial will be given esomeprazole. If you do receive this treatment 
you may or may not benefit from the effects of this drug and you may or may not have 
improvement in your pre-eclampsia. There are no other direct benefits for you being involved 
in this study. By being involved you may help us find a treatment for pre-eclampsia which could 
help many pregnant mothers in your situation in the future. 
 
What are the disadvantages of being in the study? 
 
You will need to take an extra tablet in the evenings and we may need to take a few extra 
samples of your blood for testing. 
 
What will happen if there is any new information while I am involved in the study? 
 
There will be an independent committee that will be reviewing the results of the trial on an 
ongoing basis. If there is any new information you will be informed about it and will then be 
able to decide if you would like to continue with the trial 
 
 
What will happen with the results of this research project? 
 
The results of this study will be published in medical journals and will be presented at medical 
conferences. Your private details will not be included in the articles or presentations 
 
Who has developed this study and who has reviewed the study? 
 
This study has been developed by a team of researchers from Melbourne University in Australia 
and Stellenbosch University, South Africa. We have had experts in the field of pre-eclampsia 
involved with the study. This study has been approved by the Research Ethics Committee at the 
University of Stellenbosch and by the South African Medical Research Council. 
 
Who has paid for this study? 
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This study has been funded by grants from the Medical Research Foundation for Mothers and 
Babies, and University of Melbourne. 
 
Who do I contact if I have a problem? 
 
If you have any concerns or problems you will be able to speak to the researchers involved in 
the study at anytime. If you have a more serious concern there is a safety and adverse event 
committee that you will be able to contact. 
 
This study has been approved by the Health Research Ethics Committee (HREC) at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. 
 
You can contact Dr Cathy Cluver at telephone number 082 321 0298 if you have any further 
queries or encounter any problems. 
 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have any concerns 
or complaints that have not been adequately addressed by your study doctor. 
 
If you have questions about this trial you should first discuss them with your doctor or the 
ethics committee (contact details as provided above). After you have consulted your doctor or 
the ethics committee and if they have not provided you with answers to your satisfaction, you 
should write to the South African Medicines Control Council (MCC) at: 
 
The Registrar of Medicines 
Medicines Control Council 
Department of Health 
Private Bag X828 
PRETORIA 
0001 
 
Fax: (012) 395 9201 
e-mail: mogobm@health.gov.za 
 
What do I do if I do not want to continue with the study? 
 
If you decide to not continue with the trial at any stage you may withdraw and it will not affect 
the care that you are receiving in any way. You will not be asked to give us a reason for why you 
want to withdraw from the study. We will ask you if it will be possible to collect information 
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about your pregnancy and delivery and we will ask you if it is possible for us to use the samples 
that we have already collected.  
 
Who do I speak to if I have questions about the study? 
 
If you have any questions you can discuss these with the research team, your doctor, the 
midwives involved in your care or with any of the other participants in the trial. 
 
 
 
Thank you for taking the time to read this information leaflet about the PIE trial.  
 
We hope that you will consider being involved in our study.  
 
Please keep this copy of the information leaflet. If you do decide to be involved in 
the study you will be given a copy of the consent form 
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3. PIE trial consent form 
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The Pre-eclampsia Intervention with 
Esomeprazole (PIE) trial:  
a double blind randomised, placebo-controlled 
trial to treat early onset severe preeclampsia 
 
INFORMED CONSENT FORM 
 
REFERENCE NUMBER: 
 
PRINCIPAL INVESTIGATOR: Dr Catherine Anne Cluver 
 
RESEARCH MIDWIFE: Name: ……………………………………………… 
Contact number: ……………………………… 
Email: ………………………………………………. 
                                         
ADDRESS: Department of Obstetrics and Gynaecology 
      Tygerberg Hospital and University of Stellenbosch 
 
 
 
You are being invited to take part in a research project.  Please take some time to read the patient 
information leaflet given to you which will explain the details of this project.   
 
Please ask the study staff or doctor any questions about any part of this project that you do not 
fully understand.  It is very important that you are fully satisfied that you clearly understand what 
this research entails and how you could be involved.  Also, your participation is entirely voluntary 
and you are free to decline to participate. You will be given as much time as you need to decide 
whether you would like to be involved in the study.  If you say no, this will not affect you 
negatively in any way whatsoever.  You are also free to withdraw from the study at any point, 
even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee (HREC) at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. 
 
You can contact Dr Cathy Cluver at telephone number 082 321 0298 if you have any further 
queries or encounter any problems. 
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You can contact the Health Research Ethics Committee at 021-938 9207 if you have any concerns 
or complaints that have not been adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own records. 
 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study entitled: 
The Pre-eclampsia Intervention with Esomeprazole (PIE) trial: a double blind randomised, 
placebo-controlled trial to treat early onset preeclampsia. 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in 
a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced 
in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as agreed 
to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………... 
 
 
 
......................................................................   ...................................................................  
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
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• I explained the information in this document to ………………………………….. 
• I encouraged her to ask questions and took adequate time to answer them. 
• I am satisfied that she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………... 
 
 
 
......................................................................   ...................................................................  
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) ……………..…………………………….. 
using the language medium of Afrikaans/Xhosa. 
• We encouraged her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed 
consent document and has had all her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
 
 
 
......................................................................   ...................................................................  
Signature of interpreter Signature of witness 
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4. PIE trial published correspondence 
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5. Cochrane review 
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